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Summary
Renal cancer is the 14^ most common cancer in the UK, but is the most lethal of 
urological cancers. 40% of patients present with distant métastasés, and 30% of patients 
undergoing a curative nephrectomy will subsequently develop métastasés. For localized 
disease, the mainstay of treatment is radical nephrectomy. For patients with metastatic 
disease immunotherapy is the current standard of care, though the median survival is only 
nine months. In Chapter one, the epidemiology, pathology, clinical presentation and 
treatment of renal cancer are discussed.
In the second chapter we have reported the prognostic value of the cumulative 
Glasgow Prognostic Score (based on the combination of an elevated C-reactive protein and 
hypoalbuminaemia) in patients with metastatic renal cancer commencing immunotherapy. 
The Glasgow Prognostic Score was independently associated with cancer specific survival, 
in addition to the Memorial-Sloan Kettring Cancer Centre Score, with median survivals of 
28, 11 and 3 months for patients with GPS of 0, 1 and 2 respectively. The GPS was also 
superior in predicting outcomes to another commonly used prognostic score, the Metastatic 
Renal Cancer Comprehensive Prognostic System.
In Chapter three we reported the prognostic significance of C-reactive protein, but 
not hypoalbuminaemia, in addition to the Leibovich score in UISS low and intermediate 
risk patients undergoing potentially curative nephrectomy. The presence of an elevated C- 
reactive protein was independently associated with cancer specific survival in addition to 
the Leibovich score. Both the Leibovich score and C-reactive protein were superior to the 
SSIGN score in predicting cancer specific survival.
XIV
In Chapter four we examined the role of circulating cytokines associated with T- 
lymphocyte subpopulations in patients with renal cancer. In the presence of a systemic 
inflammatory response, there was an association with increased cytokine concentrations 
from both T-helper 1 and T-helper 2 responses. However, cytokine concentrations 
measured using the Luminex technology were variable, and appeared less reliable than 
those measured using conventional ELISA technology.
In Chapter five, a longitudinal study of cytokine concentrations and circulating T- 
lymphocytes was performed in patients undergoing immunotherapy for metastatic renal 
cancer. Analysis of C-reactive protein, circulating T-lymphocytes, circulating cytokines 
was performed prior to commencement of immunotherapy, and after two to four weeks of 
treatment. Concentrations of C-reactive protein and interleukin-6 did not alter significantly 
following instigation of immunotherapy, nor did the numbers of circulating T-lymphocyte 
subsets. However, there was a significant increase in Interleukin-10 concentrations 
following commencement of immunotherapy.
In Chapter 6, we examined the longitudinal relationship between the systemic 
inflammatory response, and circulating cytokines in patients undergoing nephrectomy.
Both interleukin-6 and interleukin-10 concentrations were elevated in patients with 
evidence of a systemic inflammatory response. However, on multiple regression analysis 
only interleukin-6 was significantly correlated with C-reactive protein concentrations. 
Following nephrectomy, the proportion of patients with an elevated C-reactive protein did 
not change significantly, nor did concentrations of interleukin-6 normalise. In contrast there 
was a trend towards significance in the elevation of Interleukin-10 concentrations following 
nephrectomy.
XV
It has been previously suggested that the presence of the systemic inflammatory 
response in patients with renal cancer is due to secretion of pro-inflammatory cytokines by 
the tumour itself. It appears clear from the investigations carried out during the course of 
this thesis that the presence of systemic inflammatory response appears unlikely to be 
solely be determined by the tumour, but may be as a result of a disordered immune 
response from the host.
XVI
1.0 Introduction
1.1 Incidence
Renal cell cancer (RCC) accounts for 3% of all cancers worldwide and was 
I  ranked as the 14* most common cancer in the UK in 2004, with over 6,000 new cases per
! year(Cancer Research UK). It is approximately twice as common in men as women and
I  incidence rates increase with age with over 45% of cases occurring in patients aged over
65 (Landis et al, 1999, Office for National Statistics 2001}. The incidence of renal cancer 
I has been rising steadily over the last 50 years world-wide (Mathew et al, 2002) with the
most significant increases occurring in black population groups (Chow et al, 1999). The 
greatest proportional increase in diagnosis has been for small tumours. It has been 
proposed this is due to serendipitous detection resulting from the increased use of non­
in vasive imaging for a wide variety of urological and non-urological conditions (Jayson 
& Saunders 1998, Konnak & Grossman 1985). However, there has also been an increase 
in detection of advanced and metastatic tumours which is not explained by earlier 
detection and subsequent lead time bias (Chow et al, 1999, Hock et al, 2002). Similarly, 
the mortality rate has also increased by a small but significant amount suggesting the 
j increased incidence is not wholly due to earlier detection (Ries et al, 2001). In general, all
stages of renal cell carcinoma are increasing in incidence and it is postulated this may be 
due to an unidentified aetiological factor.
1.2 Aetiology
The majority of RCC is sporadic, though 10% of cases are related to inherited 
predispositions or syndromes. Sporadic RCC is a disease of the 5* and 6* decades of life
• though familial syndromes such as VHL may occur in younger patients.
1.2.1 Smoking
In keeping with other common cancers, smoking is associated with an increased 
! risk of developing renal cancer. In contrast to other cancers, the increased relative risk of 
cigarette smoking is only around 1.4 -  2.46, with a slightly greater risk for tobacco 
I chewers and pipe smokers though interestingly women appear to exhibit a less strong 
: association between smoking and the development of RCC (Kantor 1977, Goodman et al, 
\ 1986).
1.2.2 Hypertension
Hypertension has been linked to renal cancer, particularly uncontrolled 
hypertension and it is theorised that hypertensive damage to the nephron may initiate
* tumorigenesis. A patients with a diastolic blood pressure of 90 mmHg or greater has 
approximately twice the risk of developing RCC than a patient with a diastolic BP of
I  70mmHg or less (Chow et al, 2000). Previous studies have suggested users of diuretics 
have an small increased risk of RCC (McLaughlin et al, 1995) but on correction for 
hypertension there appears to be no excess relative risk (Mellemgaard et al, 1994). 
However, users of non-diuretic antihypertensives appear to have an increased risk even 
I with correction for hypertension (McLaughlin et al, 1995). Other renal-specific 
associations include end stage renal failure and acquired cystic disease of the kidney
which both lead to an increased incidence of papillary variant renal cancer (Ishikawa et 
al, 1993).
1.2.3 Obesity
Obesity is associated with development of a number of cancers such as breast and 
colon, but also RCC. A patient with a Body Mass Index of 30 or greater may have 
between 3 and 6 fold increased risk of developing RCC, with the effect most strongly 
reported in women. (Yu et al, 1986, Chow et al, 2000) It is postulated that this is due to 
higher levels of circulating oestrogens, or the secreted Insulin-like Growth factor -1 from 
adipose tissue (Longcope et al, 1986).
Hormone-related factors have been implicated in the aetiology of renal cancer due 
to the lesser number of women affected, the association with obesity in women, and also 
the phenomenon of renal carcinogenesis in hamsters treated with diethylstilbestrol. 
However, in human case-controlled studies there is no association between RCC and 
hormone replacement therapy and a negative association with oral contraceptive use. 
There is an increased risk of developing RCC in highly parous women, but the effect is 
not linear, and other factors such as socioeconomics may be implicated (Linblad et al, 
1995).
1.2.4 Environmental and occupational factors
Older studies have suggested RCC is an urban disease (Kantor, 1977) but the rural 
area of Bas-Rhin in France had the world’s highest incidence of RCC between 1972 and 
1992 (Mathew et al, 2002). Low socioeconomic status is associated with increased risk of 
developing renal cancer but no specific causative factor has been found (Kantor, 1977).
Occupational exposure to chemical agents has been extensively investigated with 
multiple agents postulated, but no single factor has been demonstrated to consistently and 
significantly increase risk. Occupational contacts with dry-cleaning solvents, cadmium 
and asbestos have demonstrated an increased relative risk of 1.4, 2.0 and 1.4 respectively 
though the risk is not consistent for duration of exposure and dose considerations 
(Mandel et al, 1995). There has been no association demonstrated between radiation 
exposure and RCC. Animal studies have suggested a link between hormones such as 
diethylstilboestrol, lead compounds and aflatoxins but no correlation has been shown in 
humans (Kantor, 1977).
1.2.5 Genetics
RCC describes several distinct histological subsets, and hence there are several 
distinct genetic syndromes associated with RCC development.
1.2.5(1) Von Hippel Lindau Syndrome
The most common mutation associated with the development of renal cell cancer 
is loss of the von Hippel-Lindau (vHL) tumour suppressor gene. This gene is located on 
Chromosome 3p25 and conforms to the Two-Hit Hypothesis (Kaelin et al, 1998). 
proposed by Knudson and Strong in 1972. VHL disease occurs in approximately one per
36,000 head of population and is inherited in an autosomal dominant fashion with over 
80% penetrance. Patients with VHL disease may develop multiple tumours including 
retinal angiomata, CNS haemangioblastoma and phaeochromocytomas as well as clear 
cell RCC, which may often be multi-centric or bilateral in young adults. The VHL gene 
codes for a protein which indirectly regulates the cellular response to hypoxia. It forms a 
complex with 2 other proteins (ElonginB +C) which targets a protein known as Hypoxia 
Inducible Factor la  (HIFl-a). H IF l-a  controls the transcription of a number of growth 
factors including vascular endothelial growth factor(VEGF), platelet derived growth 
factor(PDGF), transforming growth factor-a (TGF-a) and erythropoietin. Under normal 
VHL control and oxygen tension, the VHL complex is responsible for degrading H IFl-a 
and limiting the production of growth factors. Under hypoxic conditions, or if both copies 
of the VHL gene are mutated, H IF l-a is not degraded. The subsequent increase in 
production of vascular and autocrine growth factors are thought to be crucial to the 
developing neoplastic cells, and the hypervascular nature of RCC. (Linehan et al, 2003).
Careful screening of affected families is required to identify renal and other tumours at an 
early stage.
1.2.5(ii) Hereditary Papillary Renal Cancer
A further form of hereditary RCC was described in 1994 following pedigree 
studies of affected families. This is known as Hereditary Papillary Renal Carcinoma 
(HPRC) (Zbar et al, 1994). It is transmitted in an autosomal dominant fashion and has 
high and consistent penetrance. Tumours are often of later onset, in the 5* and 6* decade, 
but may be multi focal or bilateral. The gene for HPRC is located on the long arm of 
Chromosome 7 (7q31) (Linehan et al, 2003) and is a proto-oncogene. This region codes 
for the MET gene, which belongs to a family of tyrosine kinase transmembrane receptors 
responsible for sending signals from the cell surface to the cell nucleus. The MET protein 
is bound by Hepatocyte Growth Factor (HGF.) Normally when HGF binds, a growth 
stimulating cascade is stimulated. If the MET gene region becomes mutated, the receptor 
is activated without binding, leading to uncontrolled cell growth and proliferation. 
1.2.5(iii) Birt-Hogg-Dube Syndrome
Birt-Hogg-Dube Syndrome was first described as a dermatological condition in 
1977 with a triad of benign skin tumours; fibrofolliculomas, trichodiscomas and 
acrochordons appearing in the third or fourth decade of life (Birt et al, 1977). A case 
report of a patient with Birt-Hogg-Dube (BHD) syndrome and bilateral renal cancers was 
pubhshed in 1993 (Roth et al, 1993) and a population screening study identified an 
association with familial renal tumours (Toro et al, 1999). The syndrome is inherited in 
an autosomal dominant fashion with the genetic abnormality mapped to chromosome 17 
which codes for a protein called folliculin (Schmidt et al, 2001). Approximately 15-30%
of patients with BHD will develop renal tumours, though unlike the other familial 
syndromes, the pathology is variable. The most common tumour subtype is 
I  chromophobe, though oncocytic renal cell carcinomas and pure oncocytomas have also 
been reported.
1.2.5(iv) Genetic abnormalities and sporadic tumours
In cases of sporadic clear cell RCC there is loss of heterozygosity of the VHL 
gene in nearly 100% of cases with an accompanying mutation on the remaining allele in 
; 35-85% of cases (Gnarra et al, 1994, Shuin et al, 1994). Other genetic abnormalities 
; associated with clear cell RCC are the loss of genetic material from the p arm of 
chromosome 3 and gain on the q arm of chromosome 5 forming an unbalanced 
translocation (Pavlovich et al, 2003).
Unlike the VHL mutation, sporadic cases of papillary RCC express the MET 
oncogene in less than 15% of cases (Schmidt et al, 1999). Papillary RCC is also 
associated with a translocation between the Y chromosome and Chromosome 17 and also 
trisomy in Ch7 and Chl7 (Lager et al, 1995).
1.3 Presentation
1.3.1 Classical presentation
The classical presentation of RCC is a triad of symptoms and signs; haematuria, 
loin pain, and a palpable flank mass. This triad is now often referred to as the “too late 
triad” and is rarely seen, comprising less than 2% and 10% of symptomatic presentations 
in 1998 and 1971 respectively (Jayson & Saunders 1998; Skinner 1971). The overall 
presentation of RCC is changing, with increasing numbers of patients diagnosed with 
asymptomatic, incidentally detected tumours. The figures are now historical, but it was 
estimated that over 60% of renal tumours were diagnosed incidentally in the 1990s, 
compared with around 10% in the early 1970s (Jayson & Saunders 1998; Skinner 1971). 
This change has been linked to a significant increase in the use of non-invasive imaging 
such as ultrasound and CT throughout the population, and a population that is ageing as a 
whole. However, no figures regarding modes of presentation in the 21®* century have been 
published to confirm this trend.
1.3.2 Local effects
Local effects from the primary tumour may include loin pain and haematuria. 
Local invasion may cause pain, but also disruption of the invaded structure. Right sided 
tumours may invade or compress the duodenum or biliary tree leading to gastrointestinal 
symptoms and occasionally jaundice.
RCC is unique in its propensity to propagate along the venous system into the 
inferior vena cava and then cranially towards the right atrium. This involvement whether 
by tumour thrombus or direct invasion of the vessel wall may cause a number of 
presenting symptoms. These include a left-sided varicocoele, or varicocoele that persists
despite recumbency, due to obstruction of the left renal vein. Rarely, a right-sided 
varicocoele may result from extensive IVC thrombosis obstructing the right gonadal vein. 
Bilateral lower limb oedema or the presence of bilateral deep vein thrombosis may also 
result from IVC involvement. Tumour thrombus may be identified during routine 
echocardiography it if has propagated to the right atrium, or due to symptomatic 
pulmonary emboli.
1.3.3 Distant
I The pattern of métastasés in renal cancer is diverse, with a propensity for unusual
metastatic sites. Virtually every organ in the body has been recorded as a site of 
metastasis from RCC. Subsequently, symptomatic presentation of metastatic disease is 
heterogeneous, and in addition, patients may be completely asymptomatic despite 
disseminated RCC. Lung, bone and brain are among the most frequently encountered 
metastatic sites and common presenting symptoms related to these are dyspnoea, bone 
pain and neurological disturbances respectively. Cutaneous deposits are also relatively 
common though the underlying diagnosis may only be made after excision biopsy. Table
1.1 illustrates the frequency of various metastatic sites recorded in one study of patients
I with metastatic RCC (Maldayz & DeKemion, 1986).
f
1.3.4 Paraneoplastic
RCC is probably associated with the widest range of paraneoplastic phenomena of 
any tumour. Paraneoplastic syndromes are constitutional symptoms or derangement of
i  normal biochemistry or haematology which are associated with the presence of a
I
I neoplasm, though not caused directly by the tumour. They are estimated to occur in 10- 
40% of patients with RCC (Gold et al, 1996). Paraneoplastic disorders are more usually
associated with metastatic disease, but may be present in patients with localised primary 
tumours, and tend to resolve after curative resection. They can be subdivided into 
endocrine and non-endocrine syndromes, depending on the nature of the proteins secreted 
by the tumour.
Endocrine paraneoplastic effects may be due to hypersecretion of a substance 
normally associated with the kidney such as renin; or due to secretion of an abnormal 
hormone, or hormone-like protein. Syndromes associated with normal kidney secretion 
include hypertensions due to excess renin secretion, and polycythaemia secondary to 
increased erythropoietin release. Abnormal endocrine secretions include Parathormone- 
related peptide which mimics parathyroid hormone (PTH) leading to hypercalcaemia 
without bony metastatic involvement (Gold et al, 1996).
Non-endocrine paraneoplastic phenomena include weight loss, fever, night sweats 
and fatigue, and may be related to the development of a systemic inflammatory response. 
It has been suggested that these systemic symptoms are associated with IL-6 secretion 
(Blay et al, 1997). Other non-endocrine syndromes include non-metastatic hepatic 
dysfunction, known as Stauffer syndrome (Stauffer, 1961). This was first described in 
1961 where 5 cases were recorded with hepatosplenomegaly, and grossly abnormal liver 
function tests in the absence of metastatic hepatic involvement. This dysfunction is 
reversible, and biochemical parameters may return to normal after nephrectomy.
Anaemia is common despite the endocrine paraneoplastic secretion of erythropoietin. It is 
estimated that 25-33% of patients with RCC will have a normochromic normocytic 
anaemia whilst only 3% of patients will have polycythaemia (Chisholm & Roy, 1971, 
Marshall & Walsh 1977).
10
1.4 Diagnosis
Bosniak devised a classification of renal cysts based on their radiological appearance to
I stratify the likelihood of malignancy, see Table 1.2 (Bosniak 1986). The grading is based
!
I in the complexity of the cysts, and includes features such as multi-septated walls, 
calcification and enhancement after contrast administration. Solid renal lesions that 
enhance after contrast administration are said to have a 95% rate of malignancy, and the 
majority of renal tumpurs are currently diagnosed on CT imaging alone.
Fine needle aspiration biopsy (FNAB) of renal masses has a low sensitivity and 
specificity, with a false negative rate of around 10% (Rybicki et al, 2003). When 
compared with the high specificity of CT scanning, FNAB is not used routinely for 
diagnosis of RCC, though there are certain specific circumstances where renal biopsy is 
indicated. Patients with a complex renal mass and pre-existing cancer diagnosis require
‘ FNA to differentiate between renal metastasis and a second primary. Follow-up imaging
after nephrectomy may identify a further mass in the solitary kidney or renal remnant and 
confirmation of RCC would be advisable before radical surgery which may render the 
patient anephric. Tissue diagnosis via FNAB to confirm RCC is also essential in patients
I who will receive immunotherapy as first line or neoadjuvant therapy; or as part of a
clinical trial. Complications are relatively rare and those that occur most commonly are 
related to damage to adjacent structures such as bleeding and pneumothorax. Tumour 
seeding is a greatly feared complication but evidence from the literature suggests only
I
I five cases have been reported worldwide arising from biopsy of an RCC (Herts & Baker,
I  1995).
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1.5 Pathology
Renal cell carcinomas are often 5 -8 cm in gross dimensions though can vary 
extensively. Most are round or ovoid and often have a pseudocapsule of compressed renal 
tissue around them. The appearance of the tumour can be extremely heterogeneous and 
may feature yellow or tan tumour along with cysts, necrosis, haemorrhagic areas and 
calcification. The pathological classification of renal cancers was revised and simplified 
by international consensus in 1997 (Storkel et al, 1997) following advances in molecular 
genetics and greater understanding of the behaviours of the different subsets of renal 
cancer. The current classification in use was proposed by Kovacs and colleagues in 1993 
and is also referred to as the Heidelberg Classification (Kovacs et al, 1997). The 
classification defines 5 main subsets of renal cancer based on differences in genetics and 
molecular biology.
1.5.1 Conventional renal carcinoma
This is the most common form of renal cancer, and represents 70-80% of all 
cases. These tumours arise from the proximal convoluted tubule and are associated with 
loss of heterozygozity of the VHL gene on chromosome 3 in around 80% of spontaneous 
cases (Clifford et al, 1998). No other subset of RCC is associated with VHL mutation. 
These tumours are also referred to as “clear cell” due to their characteristic microscopic 
appearance. The tumour cells have an abundant cytoplasm containing glycogen and 
cholesterol which washes out during routine staining to produce the classic “clear cell.” 
The majority of studies examining treatment in metastatic RCC describe clear cell tumour 
types only.
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1.5.2 Papillary renal carcinoma
This is the second most common renal cancer, estimated to occur in 10-15% of 
cases and occasionally referred to as “chromophil renal cancer.” It is thought this tumour 
arises from more distal in the nephron than conventional renal cancer and may develop in 
an adenoma-carcinoma sequence. Papillary renal cancer occurs more frequently in 
specific populations such as those with end stage renal failure, and cystic disease of the 
kidney (Ishikawa & Kovacs, 1993). Papillary renal cancer is also more likely to be 
multicentric and tends to be hypovascular as it lacks the VHL mutation leading to 
production of VEGF and subsequent angiogenesis (Renshaw & Corlees, 1995). As well 
as the papillary architecture of malignant epithelial cells around a central fibrovascular 
core, classical microscopic features include psammoma bodies and foamy macrophages. 
Previous subdivision into basophilic and eosinophilic variants was made on the degree of 
cytoplasmic staining. This convention has now been abandoned as it is believed a 
spectrum of staining exists within the subtype rather than two distinct entities.
The genetic abnormalities most commonly encountered with cases of papillary RCC are 
trisomy of chromosome 7, 16 or 17 and a loss of the Y chromosome.
Controversy exists over outcome in papillary RCC. Blath and coworkers reported 
that 80% of papillary cancers in his series were confined to the kidney (T1 or T2) and 
often of low grade, whilst Lager’s series suggested increased numbers of higher stage and 
grade, associated with aggressive disease (Blath et al, 1976; Lager et al, 1995). It has 
been suggested that papillary renal carcinoma is subdivided into Type 1 and 2 to stratify 
the various behaviour. Type 2 tumours are larger, tend to occur in younger patients, and
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are frequently of higher stage than Type 1 tumours, explaining the apparent 
contradictions in behaviour (Delahunt & Eble, 1997).
1.5.3 Chromophobe renal cancer
Chromophobe renal carcinoma occurs in 4-5% of RCC cases and is derived from 
the cortical portion of the collecting duct. Unlike the more common subsets of renal 
cancer, chromophobe renal carcinoma is not associated with specific genetic mutations. 
Its appearance has been described as “plantlike” on microscopy as it has a transparent 
cytoplasm, and fine reticular pattern. Electron microscopy reveals characteristic 
microvesicles. In a similar fashion to papillary renal cancer, there is dispute over the 
natural history of this tumour. Thoenes and colleagues reported the behaviour of 
chromophobe tumours as low grade and often localised to the kidney, whilst Renshaw 
and co-workers depicted a high grade tumour frequently associated with metastatic 
disease (Thoenes et al, 1988; Renshaw et al, 1996).
1.5.4 Collecting Duct Renal Cell Carcinoma
This also an extremely rare form of RCC and is thought to arise from the distal 
collecting duct cells as the name suggests. Only 100 cases exist in the literature (Chao et 
al, 2002) and whilst such small numbers make inferences difficult, it is thought to affect 
younger patients, presents with advanced disease and has an aggressive course.
1.5.5 Unclassified Renal Cell Carcinoma
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It is estimated that 3-5% of renal tumours will not be classifiable by the 1997 
consensus (Kovacs et al, 1997). These tumours may have unidentifiable cell types, or 
have complete sarcomatoid features without residual renal epithelial cells. Unclassified 
tumours are often excluded from studies but have been shown to be considerably more 
aggressive, with 90% of patients having nodal disease or distant metastasis at 
presentation. (Zisman et al, 2002). Numbers are small but survival is significantly 
reduced when compared with clear cell RCC, and there is also a propensity for the 
primary tumour to be inoperable due to local invasion (Zisman et al, 2002).
1.5.6 Other tumour types 
1.5.6(1) Sarcomatoid variation
Sarcomatoid renal cell carcinoma was removed as a distinct histological subset 
during the revision of pathological subsets in 1997(Storkel etal, 1997). It is now thought 
to represent areas of poorly differentiated RCC with spindle-shaped morphology. It 
occurs in 1-5% of RCCs, particularly in conventional RCC. Sarcomatoid variation is 
associated with aggressive tumour behaviour and a poor prognosis. In two studies, over 
three-quarters of patients with sarcomatoid tumours had métastasés at presentation. 
Survival after cytoreductive nephrectomy and immunotherapy was a median 8.5 months, 
and only 5 months for patients with metastatic disease receiving immunotherapy only 
(Mian et al, 2002, Cangiano et al, 1999). If the underlying RCC tissue is not identifiable, 
the tumour is ascribed to the unclassified subset.
1.5.6(ii) Medullary renal carcinoma
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This is an exceptionally rare form of RCC first decribed in 1995 by Davis. It is 
virtually always found in patients with sickle cell trait, and is believed to develop from 
the calyceal epithelium near the renal papilla. Less than 50 cases exist in the literature 
(Figenshau et al, 1998) and it is highly aggressive with a mean survival of 15 weeks post­
nephrectomy (Davis aZ, 1995).
1.5.7 Nuclear grade
In keeping with the gross appearance of the kidney, the nuclear appearance of 
RCCs is also variable. The most commonly adopted system of classification is Fuhrman’s 
grading (Fuhrman et al, 1982), which is stratified from grade 1 through to 4 (Table 1.3). 
There can be high levels of inter-observer variability, (Al-Aynati et al, 2003) particularly 
in determining intermediate grades, and some experts have suggested simplifying the 
system into only three levels. Nuclear grade has prognostic significance independent of 
tumour stage, but is inferior to Stage in determining outcome (Fuhrman et al, 1982).
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1.6 Disease Staging
Staging of any cancer requires an understanding of the natural history of the 
disease to allow accurate risk stratification and outcome prediction. Accurate staging is 
essential for decisions regarding definitive treatment, adjuvant therapy and predictions of 
life expectancy. Use of a consistent world-wide staging system allows for comparison 
between centres and meaningful multi-centre clinical trials.
1.6.1 Current and historical staging systems
Tumour stage defines the anatomical extent of the disease. The first staging 
system used in RCC was created by Flocks and Kadesky in 1958 as a simple 4 stage 
system. It was further revised by Robson in 1969 to include vascular invasion but was 
maintained as a four stage system. (Robson 1969, Table 1.4) The Tumour-Nodes- 
Metastases system was devised by Denoix in 1948 and was used to develop the TNM 
classification for RCC by the Union Internationale Contre le Cancer in 1978. The current 
TNM classification (Table 1.5) is the 5* major revision, with further modifications 
adopted in 2001 to reflect the introduction of partial nephrectomy (Guinan et al, 1997). 
The TNM classification is now the most widely used system worldwide to stratify risk in 
patients with RCC, though some American groups still favour the Robson system. The 
strengths of the TNM classification lie in the adaptability of the classification to 
accurately represent the patient’s tumour, with 72 possible variations, combined to 
produce a 4 stage system. TNM stage classification has been shown to accurately predict 
5 year survival for patients with RCC (Bassil et al, 1985; Tsui et al, 2000a; Hermanek &
17
Schrott, 1990; Table 1.6) whilst the Robson system correlates poorly with prognosis 
(Pantuck et al, 2001).
1.6.2 Areas of controversy and potential modifications
It could be argued that some of the current controversies regarding the current 
staging system are related to areas of tumour biology still not fully understood in RCC. 
Discrimination between T1 and T2 tumours and subsequently TNM Stage I and Stage II 
is based purely on tumour size. The cut-off point between the two stages has undergone 
numerous revisions, being lowest in 1987 at 2.5 cm, and raised to 7cm in the 1997 
revision. This most recent breakpoint was chosen arbitrarily as it represented the mean 
size of tumours in the SEER database, and it had been argued that the lower 2.5cm point 
did not lead to a significant survival difference between stages. However, similar 
criticisms have been applied to the current breakpoint. A number of authors have 
examined prognosis with different size subdivisions, and the general consensus is that the 
current 7cm cut-off is too high. However, there is no clear consensus as to where the 
reduced breakpoint should be placed. Various authors have proposed new cut-offs from 
3.5 to 5.5cm (Wunderlich et al, 2002; Pi carra et al, 2004) though the most common 
breakpoint suggested is 5cm, which may be accepted in future revisions (Zucchi et al, 
2003; Elmore et al, 2003).
Adrenal involvement is more common in upper pole tumours and is estimated to 
occur in less than 5% of cases (Sagalowsky et al, 1994). Ipsilateral adrenal involvement 
is currently classified as involvement via direct spread or as a metastatic deposit, T3a and 
M l respectively. However, patients with direct invasion of the adrenal have been shown
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to have poorer prognosis than other patients with capsular penetration and perinephric fat 
invasion, other T3a tumours (Han et al, 2003). It has been proposed that adrenal 
involvement by direct spread is reclassified as T4 disease.
Nodal disease is known to convey a poorer prognosis even with a favourable T 
stage and no distant disease. The 5 year survival for patients with nodal invasion is 
estimated to be between 7 and 17% even after apparently curative nephrectomy (Bassil et 
al, 1985). In view of this, it has been suggested that N1 nodal disease should be upstaged 
to Stage IV as the outcome is clearly poorer than patients with perinephric fat or venous 
involvement in Stage III.
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1.7 Prognosis
Stage, as categorized by the TNM system, is the single most important 
determinant of outcome and prognosis in patients with RCC. Patients with Stage IV 
metastatic disease have a median survival of 9 months after diagnosis, and a 5 year 
survival of around 10%, compared to 90% survival at 5 years for patients with Stage I 
disease (Maldazys & Dekernion, 1986; Tsui et al, 2000a, Table 1.5.) Other prognostic 
factors include further tumour factors, and clinical factors, though they differ between 
metastatic RCC and localised RCC so will be dealt with sepaiately.
1.7.1 Metastatic renal cancer
Prognostic scoring systems for metastatic renal cancer tend to include a number of 
variables encompassing tumour factors, clinical factors and haematological and 
biochemical parameters, probably reflecting the heterogeneous nature of the disease. The 
Atzpodien predictive score uses 6 biochemical and clinical variables with various 
weightings to stratify patients into three prognostic categories (Atzpodien et al, 2003).
The most highly weighted variable in the system is a raised neutrophil count; with raised 
CRP, elevated lactate dehydrogenase (LDH,) time from diagnosis to metastatic disease, 
number of métastasés and the presence of bony métastasés included on univariate 
analysis but given lesser weighting. Another commonly used prognostic score is the 
Memorial-Sloan Kettering Cancer Centre system which uses low Kamofsky performace 
score, high LDH, low haemoglobin, high corrected serum calcium and absence of prior 
nephrectomy to stratify patients into three groups (Motzer et al, 1999). Further different 
variables are included in the Leibovich score for prognosis following cytoreductive
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nephrectomy, including sarcomatoid differentiation, constitutional symptoms,and 
Thyroid Stimulating Hormone levels (Leibovich et al, 2003b).
The Kamofsky performance score is used in the Memorial-Sloan Kettering 
prognostic scoring system. Performance scores reflect the impact of the disease on the 
patient and their capability to carry out normal activities, and the eponymous Kamofsky 
score was developed in 1949 as the first quantative measure of the general condition of a 
patient. The Kamofsky score has now largely been superseded by the by the Eastem 
Cooperative Oncology Group (ECOG) performance scale (Oken et al, 1982) due to its 
relative simplicity and excellent reproducibility (Blagden et al, 2003). The ECOG 
performance scale is shown in Table 1.7. It has a major role as a single independent 
prognostic factor in determining patient eligibility for entry into clinical trials. A poor 
ECOG performance status is associated with increased risk of progressive disease, 
reduced response to treatment and reduced overall survival in RCC as well as other 
tumours.
An Intemational Kidney Cancer Working Group has recently been established 
with the aim of creating a unified prognostic model for patients with metastatic RCC 
(Bukowski et al, 2004).
1.7.2 Localised renal cancer
In patients with localised tumours the important prognostic factors are closely 
linked to the discriminating factors between tumour stages in the TNM classification. 
Poorer prognosis is conferred by increasing size of the tumour, the presence of capsular 
invasion, and lymphatic or vascular invasion. The presence of nodal involvement is a
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poor prognostic factor independent of T stage. Nuclear grade, as measured by the 
Fuhrman system, is also a significant prognostic feature (Fuhrman et al, 1982).
Histological subtype may have prognostic significance with improved 5 year 
survival for patients with papillary and chromophobe shown in small studies, though in a 
recent larger study, prognostic significance was lost on multivariate analysis (Amin et al, 
2002, Patard et al, 2005). The two extremely rare subsets of RCC, medullary RCC and 
collecting duct RCC both confer an extremely poor prognosis due to the aggression of the 
tumour, along with the unclassified RCC. The presence of sarcomatoid features, or 
necrosis within the primary tumour is associated with shorter time to recurrence and 
reduced overall survival, independent of RCC tumour type (Sevinc et al, 2003). 
Microvascular invasion is also associated with poorer outcome, though this is thought to 
be due to its association with higher grade tumours (Sevinc et al, 2003).
Two major models have been developed to utilise the recognised prognostic 
tumour factors in addition to the TNM stage, both featuring the presence of intratumoral 
histological necrosis. These are the SSIGN score, which encompasses TNM stage, size, 
grade and histological necrosis (Frank et al, 2002) and the Leibovich score which 
includes T stage, nodal status, tumour size, grade and tumour necrosis (Leibovich et al, 
2003a). No consensus exists as to the superiority of one model over another.
Clinical factors are thought to be of less importance in the prognosis of localised 
tumours than in metastatic disease. Mode of presentation may have prognostic 
significance simply because increasing numbers of RCC are diagnosed incidentally, 
(Gelb, 1997), and incidental tumours tend to be of lower stage and grade, conveying a 
better prognosis (Leslie et al, 2003, Tsui et al, 2000a). The presences of specific
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paraneoplastic phenomena such as weight loss, anorexia, malaise, and hypoalbuminaemia 
have also been associated with poorer outcome independent of stage (Kim et al, 2003). 
The Memorial Sloan Kettring postoperative prognostic nomogram includes presenting 
symptoms but this variable is given significantly less weighting than tumour factors 
(Kattan et al, 2001). The only combined scoring system validated in localised renal 
cancer as well as metastatic disease is the UCLA Integrated Staging System (Zisman et 
al, 2001) which combines tumour factors of TNM Stage and Fuhrman grade with ECOG 
performance status to stratify patients into 5 groups corresponding to low, medium and 
high risk.
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1.8 Management of localised (Tl-T3a) RCC
Localised RCC describes a tumour contained within Gerota’s fascia and without 
evidence of distant métastasés. Complete surgical removal of localised disease provides 
the best outlook for disease free and overall 5 year survival. The operative management 
of localised renal cell carcinoma will be discussed in this section, including the role of 
nephron-sparing surgery, radiofrequency ablation and observation, as well as the most 
commonly performed radical nephrectomy.
1.8.1 Radical Nephrectomy
The first planned nephrectomy was performed in 1869 by Simmon, for a ureteral 
fistula. Simple nephrectomy is performed by urologists for benign and malignant 
conditions alike and entails removal of the kidney from within the perinephric fascia, 
leaving perinephric fat, adrenal and regional lymph nodes in situ. The first description of 
a radical nephrectomy with cancer principles in mind was by Robson in 1963 though 
Berg reporting from Mount Sinai hospital in 1913 suggested primary control of the renal 
vessels to prevent disseminating tumour. Robson’s operative principles were removal of 
the primary with a wide margin, early control of vessels to prevent tumour embolisation, 
and removal of potential sites of lymphatic drainage.
Robson’s radical nephrectomy involved a thoraco-abdominal approach with early 
ligation of the renal artery. The kidney and tumour would be removed in continuity with 
perinephric fat within Gerota’s fascia, including the ipsilateral adrenal. Ideally nodal 
dissection would be carried out as part of the main dissection of tumour, but often due to 
the size of the tumour, lymphadenectomy would need to be performed following removal
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of the kidney. His study reported a 5 year survival rate of 66% following radical 
nephrectomy for Stage 1 tumours and 64% for Stage 2 tumours, a significant 
improvement in comparison with simple nephrectomy. His results in 1969 demonstrated 
a statistically significant improvement in 5 year survival following radical nephrectomy, 
with an overall 5 year survival of 66% for patients with localised disease. It has been 
suggested his excellent results were partly due to precise exclusion of patients with early 
metastatic disease with use of novel imaging techniques such as CT and mediastinoscopy.
There have been subsequent modifications to Robson’s classical radical 
nephrectomy. The rate of adrenal involvement is around 10% overall and may be as low 
as 0.6% in Stage I lower pole tumours (Tsui et al, 2000b). It is believed the majority of 
adrenal involvement develops from direct extension in upper pole tumours, rather than 
haematogenous spread. It has been proposed that the indications for ipsilateral 
adrenalectomy include an abnormal adrenal on CT, upper pole tumour or involvement of 
the left renal vein, otherwise the adrenal can be left in situ (Sagalowsky et al, 1994; Tsui 
et al 2000b).
Robson’s initial paper reported involvement of regional nodes in 22.7% of cases. 
Lymph node involvement confers poor prognosis even with a favourable T stage and 
absence of métastasés, though controversy still exists regarding the role of routine 
lymphadenectomy as part of radical nephrectomy. The role of lymphadenectomy is to 
further stratify patients, allowing consideration for adjuvant therapy for those with node 
positive disease; whilst removing those with poorer prognosis from the localised disease 
group, improving this group’s survival figures. The morbidity associated with 
lymphadenectomy is relatively low, though it adds time and complexity to the operation.
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and it has been suggested that the scientific principles behind it are erroneous. The 
lymphatic drainage varies between left and right kidney. The left drains via an anterior 
and posterior group to involve the left lateral lumbar, left diaphragmatic, pre- and post- 
aortic nodes; whilst the right kidney has three main regions of lymphatic, posterior, 
anterior, and middle channels which drain to the lateral caval, pre- and post- caval and 
inter-aortocaval nodes. However, only the regional groups of nodes drain predictably, and 
there are also multiple small interconnecting lymphatic channels between regions 
(Marshall & Powell, 1982). Metastatic disease commonly occurs without enlargement of 
the regional lymph nodes, as the disease does not progress in a stepwise fashion (Pantuck 
et al, 2003). Lymph node enlargement on pre-operative CT staging is commonly due to 
reactive inflammatory nodes rather than micrometastases (Studer et al, 1990). Primary 
results only are available from the EORTC (European Organisation for Research and 
Treatment of Cancer) prospective randomised controlled trial No. 30881 comparing 
radical nephrectomy alone with radical nephrectomy and lymph node dissection. Early 
results suggest no difference between surgical outcomes (Blom et al, 1999), but no long­
term results have been published to compare oncological outcomes. It has been shown 
that very few patients, 2% on one study, will have positive nodes without clinical 
suspicion either at laparotomy or pre-operative screening, and it is proposed that nodal 
dissection is not performed routinely unless otherwise indicated (Minervini et al, 2001).
Developments in laparoscopic surgery have led to description of the laparoscopic 
radical nephrectomy as the gold standard for surgical management of RCC. The first 
laparoscopic nephrectomy was performed in 1990 for an oncocytoma by daym an and 
co-workers (daym an et al, 1991). Laparoscopic nephrectomy is performed most
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commonly via the transperitoneal approach, though increasingly the retroperitoneal 
approach is used (Allan et al, 2001). Laparoscopy has shown favourable surgical 
outcomes when compared with open surgery, with similar operative complication rates, 
but significantly shorter post-operative stay and convalescence (Kavoussi etal, 1993). 
Many of the initial studies on laparoscopic radical nephrectomy were based on short-term 
outcomes, and did not have the long-term follow-up to fully compare oncological 
efficacy (McDougall et al, 1996; Ono et al, 1997). Longitudinal studies comparing the 
oncological efficacy of open radical nephrectomy with laparoscopic nephrectomy over 10 
years are currently awaited to confirm laparoscopic nephrectomy is indeed the new gold 
standard.
1.8.2 Nephron-sparing surgery (NSS)
Nephron-sparing surgery has been pioneered due to the increasing numbers of 
patients with bilateral tumours, both synchronous and metachronous, the VHL 
population, and those with an anatomical or functional single kidney with unilateral 
tumours. The aim is to give surgical clearance whilst preserving as much healthy kidney 
as possible, and reconstructing the collecting system as necessary. Vermooten was the 
first to describe the feasibility of nephron-sparing surgery in the 1950s but was oblivious 
to the possibility of multi-centric tumours, or the presence of vascular and lymphatic 
invasion. Following Robson’s work on radical nephrectomy, techniques of partial 
nephrectomy were developed in the mid sixties (Morgan & Zincke, 1990) and included 
simple enucleation, partial nephrectomy, and extracorporeal excision with 
autotransplantation. The latter has been shown to have significantly higher complications
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and has been essentially abandoned. The current practice is to perform an extraperitoneal 
approach to the kidney and mobilise the vessels. Small peripheral tumours may not 
require temporary occlusion of the renal vein and artery, but larger and more centrally 
placed tumours usually do. The tumour and overlying perinephric fat is resected with a 
cuff of at least 0.5 cm of normal kidney. In order to reduce ischaemic damage to the 
remainder of the kidney, mannitol is given before vessel occlusion, and the kidney 
remnant is cooled with ice (Uzzo & Novick, 2001; Herr, 1999.) Some centres use intra­
operative ultrasound to confirm intra-renal extent of tumours, and it is also recommended 
that frozen section is used to confirm the excision margins are clear before repairing the 
kidney (Uzzo & Novick, 2001).
Partial nephrectomy gained popularity to obviate the need for long-term dialysis 
in certain patients, but in its infancy, surgeons experienced technical problems with 45% 
of patients developing a urinary fistula, and one third of patients developing acute renal 
failure in the post-operative period (Campbell et al, 1994). Fortunately, the discovery that 
urinary fistulas respond well to expectant management and endoscopic stenting improved 
outcomes and reduced the requirements for further open surgery.
The major concern regarding nephron-sparing surgery is the potentially increased 
risk of local recurrence. It has been suggested that patients with small peripherally 
located tumours should be offered partial nephrectomy despite a normal contralateral 
kidney (Herr et al, 1999) but this can only be done if partial nephrectomy is of equal 
oncological effectiveness. Cancer free survival after nephron-sparing surgery has been 
shown to be significantly better in patients with tumours less than 4 cm (Hafez et al, 
1999) and has led to the subclassification of the T1 tumour into T la  (<4cm) and T ib
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(4cm -  7cm)in the 2001 revision of the TNM staging system. Fergany and co-workers 
have also reported that results from nephron-sparing surgery are comparable to results 
from radical nephrectomy over 10 year follow-up (Fergany et al, 2000).
1.8.3 Minimally invasive therapy 
1.8.3(i) Radiofrequency ablation
Radiofrequency ablation of tumours using a needle electrode to cause local 
heating and tissue destruction was initially developed for small metastatic liver lesions. It 
was noted that the heating and tissue destruction were remarkably constant in ex vivo use, 
(Zlotta et al, 1997) and the first case report of successful radiofrequency ablation of a 
human renal cancer was described in 1998 by McGovern. Early follow-up suggests 
promising results and as the procedure appears well tolerated under conscious sedation 
(Pavlovich et al, 2002) this treatment may well be used increasingly in the elderly 
population who are unfit for a general anaesthetic as well as those with hereditary or 
multiple tumours, though it is still an considered an experimental technique.
1.8.3(ii) Cryotherapy
Similar to RFA, cryotherapy was pioneered on hepatic lesions, with the first use 
on a human RCC in vivo reported in 1996 (Delworth et al, 1996). Cryotherapy is usually 
delivered using an argon gas probe, and has two phases of tissue destruction. Initial 
freezing produces an iceball with total destruction of all tissue through rupture of cell 
membranes up to the few millimetres in the periphery. Subsequent thawing allows 
circulation to return with development of an acute inflammatory response in the residual 
tissue, thought to be due to damage to endothelial cells (Anderson & Havranek, 2004).
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Again, long-term follow-up is limited, but promising results have been reported following 
cryotherapy for small tumours in patients unfit for nephrectomy (Gill et al, 2005).
1.8.4 Observation.
Despite advances in surgical technique and anaesthesia, nephrectomy remains a 
major operation, and in patients with significant co-morbidity complication rates are high. 
Due to this, and the increasing number of asymptomatic tumours discovered, a policy of 
watchful waiting has been suggested in RCC. The first advocate of the watchful waiting 
policy was Berg in 1913 though his stance was derived from the high mortality rate of 
early operative intervention for RCC. Bosniak has suggested that small tumours have a 
slow growth rate and lesser propensity to metastasis (Bosniak, 1995). These findings are 
supported in a larger study by Lamb and colleagues who reported growth rate as 
independent of tumour size, with metastasis a rare event in the cohort of elderly patients 
who were actively observed (Lamb et al, 2004).
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1.9 Management of locally advanced renal cancer
1.9.1 T3b and T3c tumours
Renal cancer is unique in its propensity for tumour thrombus propagation into the 
renal vein and the inferior vena cava (IVC) and right atrium. JVC involvement is 
estimated to occur in 4-10% of cases of RCC (Marshall et al, 1970). Accurate pre­
operative imaging of the tumour is required, not only regarding the level of caval tumour 
extension, but also regarding the presence of distant métastasés as there is currently no 
evidence to demonstrate any survival benefit for patients undergoing nephrectomy and 
caval exploration with concurrent distant métastasés (Bissada et al, 2003). Suprahepatic 
extension of tumour thrombus may necessitate the planned involvement of hepatic or 
cardiothoracic surgeon to perform hepatic mobilisation, cardiac bypass, and rarely 
cardioplegia to allow for vessel control and thrombectomy (Jibiki et al, 2004;
Langenburg etal, 1994).
The mainstay of treatment in T3b or T3c disease is radical surgery, aiming to 
remove all tumour with negative surgical margins. The first published description of 
caval exploration with nephrectomy is by Berg in 1913 who described gaining initial 
control of the renal vessels, followed by caval clamping and milking out of tumour 
thrombus in 6 patients with only 1 death. It took until 1972 for RCC with caval extension 
to be thought of as a potentially curable lesion, with successful resection in 75% of 
patients (Skinner et al, 1972). An improvement in surgical techniques, including hepatic 
mobilisation, cardiopulmonary bypass, and the use of prosthetic grafts to replace resected 
portions of IVC have all lead to increasing numbers of patients with T3b tumours having 
successful resections (Bissada et al, 2003).
31
There has been controversy over the revision of the TNM classification in 1997 to 
classify renal vein and infra-diaphragmatic IVC involvement as T3b, based on the 
evidence that no statistically significant difference in prognosis has been reported 
between patients with renal vein involvement alone, and renal vein and inferior vena cava 
involvement below the diaphragm (Kim et al, 2004). However, tumour extension above 
the diaphragm has a significantly worse prognosis and has been classified as T3c to 
reflect the poorer outcome (Sosa et al, 1984). As with localised disease, the presence of 
regional lymph node métastasés is an independent prognostic sign of poor outcome 
(Kuczyk et al, 1997). It is also important to differentiate IVC involvement as either 
tumour thombus propagation or direct vessel wall invasion, as these have different 
prognostic values. Tumour thrombus present in the IVC can be milked out relatively 
easily and 5-year survival rates are around 68%. In contrast, invasion of the caval wall 
with positive surgical margins has a 5 -year survival rate of 26%, rising to 57% if the 
involved caval wall is fully resected (Hatcher et al, 1991).
1.9.2 T4 tumours
T4 tumours in the TNM classification are tumours that have extended outwith 
Gerotas fascia and may have invaded into adjacent structures. Patients may present with 
pain from invasion of local nerve roots, or paraspinous muscles, but many still have 
incidentally detected tumours despite the advanced tumour stage.
The primary consideration of the surgeon treating a patient with a T4 tumour is 
whether the disease is resectable. The results from simply debulking tumours have been 
very poor; with 1 year survival rates of around 12% (DeKemion 1978). Radical surgery
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may require excision of neighbouring structures such as colon, pancreas and diaphragm 
to provide clear excision margins. In patients with apparently unresectable disease and 
good performance status, neo-adjuvant immuno-therapy may be advocated in the hope 
even a partial response may render the tumour operable. However, there is a striking lack 
of literature regarding neo-adjuvant immunotherapy and the management of patients with 
T4 disease in general.
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1.10 Adjuvant therapy following nephrectomy for patients at high risk of
recurrence
Despite improvements in diagnosis and also improvements in surgical technique, 
many patients are at high risk of recurrence following an apparently curative 
nephrectomy and relapse rates may be as high as 30% (Sandock et al, 1995). High-risk 
groups include patients with nodal disease, patients with macroscopic venous or 
micro vascular invasion and also patients with positive surgical margins. A variety of 
adjuvant therapies have been tried to reduce the recurrence rates and hence improve 
overall survival in this group.
1.10.1 Radiotherapy
A number of studies have examined the role of post-operative radiotherapy to the 
renal bed following nephrectomy following the success of the BAUS series in the fifties 
(Riches, 1966) which suggested an increased survival benefit and reduced recurrence 
rate. However, this series was published before uniform staging systems were 
widespread. Repeat studies based on standard pathological classification demonstrated no 
survival benefit or increased time to recurrence with post-operative radiotherapy using a 
number of regimes (Finney, 1973; Kjaer et al, 1986.) The effects of radiotherapy on 
neighbouring organs, in particular the liver, duodenum, and small bowel, have been 
shown to increase morbidity and mortality and adjuvant radiotherapy for RCC has 
become essentially obsolete.
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1.10.2 Immunotherapy
A number of clinical trials have used immunotherapy in an adjuvant role to 
prevent recurrence by stimulating immune surveillance. Treatment with interferon-alpha 
has not been associated with any delay in time to recurrence or reduced incidence of 
disease recurrence in several trials (Porzsolt et al, 2001; Pizzocaro, 1992).
At present there is no standard adjuvant treatment for patients at high risk of recurrence 
and they require intensive follow-up to allow for early detection and treatment of 
métastasés. A Europe-wide Phase III trial “HYDRA” is currently running to establish the 
efficacy of combination immunochemotherapy in the form of IL-2, 5-FU and IFN-a in 
comparison with observation alone as an adjuvant therapy for high risk patients with 
recruitment closing in July 2006.
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1.11 Management of metastatic disease
Several modalities of treatment have been used in metastatic disease and these 
will be addressed in turn. The overall outlook for patients with distant métastasés is poor, 
with a 5 year survival rate of around 10% (DeKemion, 1978). The phenomenon of 
spontaneous regression of RCC is estimated to occur in less than 1% of cases (Young 
1998) but it has been suggested spontaneous resolution may explain the similarity of 
responses in patients treated in both placebo and active arms of clinical trials (Oliver et 
al, 1989).
1.11.1 Chemotherapy
Metastatic renal cell ca is relatively chemotherapy insensitive. A meta-review of 
33 chemotherapy agents in 51 Phase II trials was carried out, which involved 1,347 
patients (Motzer & Russo, 2000). No chemotherapy drug produced significant response 
rates to support single agent chemotherapy as a treatment option for patients with 
metastatic RCC. Combination chemotherapy regimes and chemotherapy plus hormonal 
agents also produced no increase in rates with additional toxicity
Chemoresistance in RCC is due to underlying cell biology. RCC cells produce P- 
glycoprotein, the protein product of the MDR-1 gene (multi drug resistant) gene. This 
plasma membrane protein provides an ATP driven mechanism for transporting 
hydrophobic drugs from intracellular to extracellular. It actively effluxes many 
chemotherapeutic agents, including vinka alkaloids, promoting broad resistance (Mickish 
et al, 1990). However, agents used to block the MDR protein such as verapamil have not 
improved responses when used in combination with chemotherapy (Yagoda et al, 1995)
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and other features of tumour biology may also be important in the chemoresistance of 
RCC.
1.11.2 Radiotherapy
Renal cell carcinoma is also relatively radio-resistant. The main role of 
radiotherapy in metastatic renal cancer is for symptom control in a palliative setting. This 
may be appropriate for symptoms from the primary tumour such as pain, or continuing 
haemorrhage, though is more commonly used for symptoms from metastatic disease. 
Indications for radiotherapy in metastatic disease include haemorrhage, bone pain, 
tumour mass effects, and neurological symptoms from cord involvement or brain 
métastasés. Relatively small doses are highly effective in reducing symptoms from bony 
métastasés. However, radiotherapy is less effective in the treatment of neurological 
métastasés than neurosurgery in patients with an isolated recurrence and a good 
performance status (Halperrin & Harisiadis, 1983).
1.11.3 Hormonal therapy
In animal studies oestrogen has been used to produce renal cancers in rodents, 
particularly hamsters and subsequent use of antioestrogens blocked tumour induction (Li 
& Li, 1984). Despite this, no role has been identified for endocrine blockade such as 
tamoxifen in treating metastatic RCC (Atzpodien et al, 2001) and immunohistochemisty 
suggests minimal androgen receptor expression within renal tumours (Langner et al, 
2004).
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Both medroxyprogesterone acetate (Provera) and Megestrol acetate (Megace) have been 
used in metastatic RCC on a limited basis. Neither drug has shown an increased response 
rate to suggest anti-tumour activity but both have been used in patients in advanced 
disease for palliative purposes (Schacter et al, 1989; Harris, 1983.) Both increase appetite 
and may improve fatigue, particularly in patients with cachexia and it is reported that 
minimal adrenal suppression may reduce the systemic inflammatory response driving the 
cachexia (Naing et al, 1999).
1.11.4 Immunotherapy
Immunotherapy is treatment using cytokine preparations to stimulate or modify 
the body’s immune response. The two main types of immunotherapy used are the 
interferons and interleukins.
1.11.4(i) Interferons
Interferons are a family of proteins containing around 166 amino acids and were 
first discovered in the 1950s as antiviral agents, named due to their “interference” with 
viral replication. They are coded for by a number of genes on chromosome 9 in 
leucoyctes and monocytes (Dorr, 1993). In vivo the amino acids in the molecule are 
bound to an essentially inert sugar molecule to produce a molecular weight of around 
37,000D. There are three main subgroups, interferon-a, p and y. The exact mechanism of 
action of IFN is as yet unclear. Cell surfaces carry a specific IFN receptor which allows 
for internalisation of the IFN. Within the cell, IFN activates a specific protein kinase 
which binds to double stranded RNA, blocking RNA synthesis and protein production. 
IFN also inhibits a number of oncogenes including c-myc and c-fos and the gene coding
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for an enxyme ornithine decarboxylase (Dorr, 1993). This is believed to be the underlying 
mechanism of IFN’s activity in slowing cell division and increasing the time cells spend 
in the resting (GO) phase. A number of tumours including non-small cell lung cancer, 
glioma and acute lymphoblastic leukaemia show a deletion of the area on chromosome 9 
responsible for interferons, (Olopade et al, 1993; Diaz et al, 1990) leading to suggestions 
that IFNa is a natural tumour inhibitor.
Interferons have a significant number of immunoregulatory actions. They can 
activate monocytes and macrophages, induce tumour antigen expression, increase natural 
killer and cytotoxic T-cell acitivity. Interferons have also been shown to modify the T 
helper differentiation in murine studies. IFNy is released by TH-1 cells, and in turn 
inhibits TH-2 cells (Dorr et al, 1993). Patients with RCC have a predominantly TH-2 
response and IFN may help to downregulate this in favour for T-cell maturation.
IFNs have a weak antiangiogenic action, but even when used in high dose and in 
combination with other anti an giogenic agents to treat RCC results have been 
disappointing (Hemberg et al, 2003).
Interferon-y has appeared to be a more active immune modulator in vivo than 
other subgroups but Phase III trials administering IFN-y have suggested its response rate 
in patients with metastatic RCC is no better than placebo (Venner et al, 1997; Gleave et 
al, 1998). Its use has now been discontinued in favour of IFN-a in clinical trials.
Artificial or therapeutic IFNa is produced by recombinant DNA technology and 
administered by subcutaneous injection. The optimum dosage and administration regime 
varies between country and trial group but it is generally established that low-to medium 
doses of around 10 megaunits intermittently are as effective as continuous high doses
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(Krown, 1987). The dose and duration of treatment usually is limited by patient tolerance 
of side effects, though one study has shown patients with stable disease may tolerate 
more than 12 months of treatment (Kankuri et al, 2001). The Medical Research Council 
trial of IFNa versus medroxyprogesterone acetate reported a 12% improvement in 
survival in the IFN group, an improvement in median survival of 2.5 months (MRCC, 
1999).
Responses to IFN vary, and have been reported as between 12 and 30 % 
(DeKemion 1983; Neidhart 1986). However, some trials have considered stable disease 
to be evidence of a response to IFN, whilst others have defined a response to be at least a 
50% reduction in the disease. The average time to an objective response is between 2 and 
4 months (Wirth, 1993) though responses after more than 1 year’s treatment have been 
reported (Kankuri et al, 2001).The average duration of response has been shown to be 
between 8 and 10 months though on rare occasions may be sustained for 24 months 
(Wirth, 1993). Highest response rates reported tend to come from specialist centres and 
are probably due to careful patient selection. Improved outcomes are reported in 
asymptomatic patients with high performance status, previous nephrectomy, and low 
volume pulmonary métastasés (Minasian et al, 1993). Other factors predictive of 
favourable response are the absence of a systemic inflammatory response (Bromwich et 
al, 2004) and normal white cell count (Royston et al, 2004).
Side-effects can be considerable and lead to a significant deterioration in ECOG- 
PS. They include fatigue, nausea, flu-like symptoms, diarrhoea and itch and whilst 
modulated to some degree with paracetamol may require dose reduction or even 
treatment cessation in severe cases.
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1.11.4(ii) Interleukins
Interleukin-2 was discovered as part of the search for T-cell growth factors in 
1976. Interleukin-2 is primarily a cytokine of the TH-1 response and is a 15,000 dalton 
glycoprotein secreted by activated CD4+ lymphocytes. Its effects are T-cell proliferation 
and differentiation, and it also enhances natural killer cell function, and causes 
proliferation of granular lymphocytes which develop as lymphokine-activated killer cells 
(LAK) Its anti tumour activity is primarily through immunological actions as it has no 
direct antiproliferative actions (Gitlitz & Figlin, 2003). High dose intravenous IL-2 was 
approved as a treatment for metastatic RCC in 1992 by the American FDA following 
overall response rates of 15% in Phase III trials with 255 patients (Fyfe et al, 1995).
There was a significant increase in the duration of the response with a median response of 
23 months, and also in complete responses, though responses only occurred in patients 
with an ECOG PS of 0 or 1.
Toxicity is the major concern in patients treated with high-dose IL-2, with side- 
effects including hypotension, and cardiac problems which have been fatal, with a 4% 
incidence of treatment-related death reported (Fyfe et al, 1995). The underlying 
mechanism of toxicity appears to be increased capillary permeability leading to 
hypotension and pulmonary oedema (Haas et al, 1993). Side effects are dose-dependent, 
and considerable adjustment has been made to minimise side effects whilst preserving 
response rates. Attempts to reduce side-effects with regimens of subcutaneous low-dose 
IL-2 has produced better tolerance, with similar response rates, though it is suspected 
responses may be of a shorter duration (Law et al, 1995.) It has also been suggested that a
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rapid deterioration in a patients’ quality of life whilst receiving IL-2 is associated with a 
better outcome, which may motivate patients to persevere with treatment (Atzpodien et 
al, 2003b).
Relatively new mechanisms of administration have included local use of IL-2 to 
reduce systemic side-effects such as inhaled IL-2 for pulmonary métastasés. This has 
been trialled in high risk patients and has been associated with increased stable disease 
rather than any objective response (Huland & Heinzer, 2004).
1.11.5 Combination chemo/immunotherapy
Early studies of both IFNa and IL-2 suggested that the different mechanisms of 
action could lead to synergy from combined therapy. However in a multi-centre trial, 
response rates from dual therapy were similar to those of IL-2 alone, but with additional 
toxicities (Vogelzang et al, 1993). One large study has demonstrated a significant 
increase in response rates to 18.6% in patients treated with dual therapy, when compared 
with monotherapy interleukin-2 or interferon alfa with responses of 7.5% and 6.5% 
respectively (Negrier et al, 1998). However, the overall survival rates showed no 
difference between those receiving single therapy and dual therapy.
Experimental and Phase II studies have also suggested a synergistic effect 
between fluorouracil and interferon-a. A biochemotherapy triple regime of interleukin-2, 
interferon-alpha and fluorouracil over an eight week cycle, pioneered by Atzpodien has 
reported response rates of over 40 % and with similar toxicities to dual immunotherapy 
(Atzpodien et al, 1993). Whilst some centres running Phase II trials have achieved similar 
response rates of 35%, (Hofmockel et al, 1996) other clinical trial centres have shown no
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additional benefit from the addition of 5-FU to the dual therapy of interleukin-2 and 
interferon-a (Negrier et al, 2000). It has been argued that the lack of reproducibility with 
the triple regime represents a less highly selected group of patients with poorer prognostic 
factors. Currently a European multicentre randomised trial is in progress to compare 
“triple therapy” with IFN alone in patients with metastatic RCC (EORTC 79).
1.11.6 Multi-modality therapy
Increased response rates to Interferon and Interleukin-2 have been recorded in 
patients with metastatic RCC who have undergone nephrectomy, so known as 
cytoreductive nephrectomy. However, nephrectomy alone has no survival benefit in 
patients with metastatic renal cancer (Middleton, 1967) and in patients unfit for 
subsequent immunotherapy nephrectomy should only be performed for palliative reasons 
such as haemorrhage. It is believed that removal of the large primary tumour may at least 
partially reverse any immunosuppressive effect prior to stimulatory immunotherapy. 
Similarly, even multiple pulmonary métastasés are of relatively low volume when 
compared with an in situ renal primary, hence the “cytoreductive” role of nephrectomy. 
Surgery followed by immunotherapy with interferon led to a survival advantage of 5.8 
months respectively when compared with interferon alone (Flanigan et al, 2004).
Controversy exists over the timing of immunotherapy and cytoreductive 
nephrectomy. A survival advantage exists for those patients who have undergone primary 
nephrectomy but performing major surgery on patients with a relatively poor survival 
may be inappropriate. Patients may have a delayed recovery following their nephrectomy, 
deterioration in performance status, or operative complications such as myocardial
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infarction which would render them unsuitable for IL-2 therapy. Patients with rapidly 
progressive disease may also not be deemed suitable for a trial of immunotherapy after 
surgery. A number of studies have reported that approximately 40% of patients who 
undergo cytoreductive nephrectomy subsequently do not receive post-operative 
immunotherapy, usually due to operative morbidity or disease progression (Walther et al, 
1993). The only significant factor predicting failure to undergo immunotherapy in these 
studies was a pre-operative ECOG PS of 2 or greater which emphasises the importance of 
careful patient selection for multi-modality therapy. Despite a policy of active 
consideration for surgery, the numbers of patients suitable for primary cytoreductive 
nephrectomy are small and represent seven percent of all patients with renal cancer 
(Bromwich et al, 2002).
It has also been proposed that immunotherapy should be given initially as a 
neoadjuvant treatment (Sella et al, 1993). Patients who respond to immunotherapy would 
then undergo cytoreductive nephrectomy and radical excision of any remaining 
métastasés. Advantages of this approach include better selection of patients undergoing 
the major procedure of a nephrectomy, and potential shrinkage of the primary leading to 
enhanced operability. However, numbers undergoing nephrectomy would be even smaller 
than the current rates for cytoreductive nephrectomy. One study has suggested slight 
survival benefit of 14 months compared with 12 months for patients treated with initial 
immunotherapy but numbers were small (Rackley et al, 1994). At present the Southwest 
Oncology Group (SWOG) is running a multicentre trial to compare these two treatment 
regimes though no results have been published to date.
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1.11.7 Surgery for metastatic disease
Whilst the mainstay of treatment in patients with metastatic RCC is 
immunotherapy, either alone or as part of a clinical trial, there are specific indications 
where surgery can play a useful role in the treatment of metastatic disease.
The first role is in the treatment of the isolated local recurrence. This is a 
relatively rare occurrence and is estimated to occur in less than five percent of patients 
within five years of the potentially curative nephrectomy (Itano et al, 2000). Controversy 
exists as to whether renal bed recurrence represents microscopic residual disease from the 
time of nephrectomy, or a specific form of metastatic disease. In these patients, complete 
surgical excision of residual tumour including any adjacent involved organs is essential to 
maximise disease-free survival. The five year survival rate for patients undergoing 
successful en-bloc resection of recurrence is approximately 50% whilst conservative 
treatment or immunotherapy carries a five year survival of around 15% (Itano et al, 2000; 
Sandhu et al, 2005).
The second indication for surgery in metastatic disease is in patients with discrete 
single métastasés or low volume disease. In these patients, careful evaluation needs to be 
made to ensure there are no other concomitant métastasés as it is estimated that the 
incidence of a solitary metastasis is approximately two and a half percent (O’Dea et al, 
1978). The first description of successful surgery for solitary pulmonary métastasés was 
in 1939, with the patient living 23 years after surgery (Middleton, 1967). Metastasectomy 
is most commonly carried out for pulmonary métastasés in the form of wedge resection 
or lobectomy, but can also include partial liver resection, adrenalectomy and soft tissue 
resection. There is a significant survival benefit for those presenting with a solitary
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metastasis some time after their primary tumour when compared to patients with 
concomitant metastasis and primary tumour, with 50% survival at five years, and 22% at 
two years respectively (O’Dea et al, 1978). The site of metastasis may also have 
prognostic significance as work by O’Dea suggested patients with solitary bony 
métastasés had a relatively poorer outcome, though more recent work from a specialised 
Orthopaedic Oncology unit reports a five year survival of approximately 50% for patients 
with favourable characteristics treated aggressively with surgical resection (Althausen et 
al, 1997). In some circumstances, such as recurrent solitary pulmonary métastasés, repeat 
metastasectomy may be appropriate but should not be performed if there is evidence of 
disseminated disease (Fourquier et al, 1997).
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1.12 RESEARCH PROPOSAL
Examining the prognostic indicators in metastatic and localised RCC, various 
aspects of the systemic inflammatory response, namely neutrophil count and CRP, are 
clearly associated with poorer outcomes. Recently a cumulative prognostic score based 
on elevated CRP and hypoalbuminaemia, markers of the systemic inflammatory 
response, has been developed. This has been shown to have prognostic value in patients 
with non-small-cell lung cancer, independent of stage and performance status (Forrest et 
al, 2003.) The value of this prognostic score has yet to be examined in metastatic or 
localised RCC.
1.12.1 CRP and Renal Cancer
C-reactive protein (CRP) was first discovered in 1930 and is the prototypical 
acute phase protein. In response to infection or injury, hepatic synthesis can rapidly 
increase its circulating concentration up to one thousand fold (Gabay et al, 1999, see Fig 
1.1). Its secretion is thought to be primarily regulated by Interleukin-6 (IL-6,) and 
corticosteroids, though the mechanism controlling secretion is not fully understood 
(Black et al, 2004) CRP has both pro-inflammatory and anti-inflammatory activities. It 
activates complement and enhances phagocytosis, stimulates IL-8 release, a strong 
chemotactant factor for neutrophils, and increases the release of IL-1, IL-6 and IL-18. 
However, it also induces IL-lRa expression, and may increase secretion of IL-10 whilst 
decreasing secretion of interferon-y. CRP has a protective role against bacterial infection 
though requires synergism with the complement system. CRP is the most widely used 
determinant of the presence of a systemic inflammatory response in vivo as CRP
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concentrations have no clinical variations with age or gender, and are readily measured 
by standardised reliable assays (Gabay et al, 1999).
The underlying stimulus driving CRP secretion in RCC has yet to be established.
It has also to be determined whether abnormalities in the host immune system lead to the 
development of an inflammatory response, or whether this is in response to secretions 
from the tumour itself.
1.12. 2 Interleukin-6 and Renal Cancer
IL-6 was first described in 1985 as a “B-cell differentiation factor (BSF-2).” It is a 26 
kDa cytokine synthesised by macrophages and vascular endothelial cells in response to 
IL-1 and TNF. It is a pro-inflammatory cytokine, and also has importance in regulating 
the Thl/Th2 balance (Fig 1.2). It acts on hepatocytes in association with IL-1 and TNF to 
trigger synthesis of acute phase proteins, particularly CRP secretion.
1.12. 2(i) Interleukin-6 and advanced cancer
Serum IL-6 has been shown to be a prognostic indicator similar to CRP in patients 
with metastatic RCC undergoing immunotherapy with IL-2. Patients with detectable IL-6 
or a CRP >50mg/l were found to have a poorer response rate to immunotherapy, and a 
shorter overall survival (Blay et al, 1992). The presence of paraneoplastic syndromes in 
association with RCC is well-documented. IL-6 concentrations have been found to be 
significantly higher in patients with paraneoplastic phenomena such as weight loss, 
pyrexia, hypoalbuminaemia and Stauffer syndrome (Blay et al, 1997; McLellan et al, 
1998). Levels of serum IL-6 are higher in patients with metastatic RCC when compared
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with localised disease, (Ljungberg et al, 1997) with one study suggesting over 70% of 
patients with metastatic RCC had elevated serum IL-6 concentrations (Negrier et al, 
2004).
1.12.2(ii) Interleukin-6 and localised disease
An increased expression of IL-6 has been associated with higher grade tumours 
(Paule et al, 2000) and also in higher tumour stage (Ljungberg et al, 1997). Yoshida and 
co-workers have also reported similar findings of increased concentrations of serum IL-6 
in patients with higher grade tumours, and an association between IL-6 and tumour size 
in RCC (Yoshida et al, 2002). This group also confirmed the association between serum 
IL-6 levels and CRP without examining the underlying mechanism. In 1989, Miki and 
co-workers demonstrated the expression of IL-6 mRNA in freshly isolated RCC cells, 
and proposed that IL-6 behaved as an autocrine growth factor tissue for RCC in vitro. 
Further work by Takenawa and colleagues confirmed the secretion of IL-6 by RCC cell 
lines, and the presence of IL-6 receptor within cell lines and fresh RCC tissue. An 
association between raised IL-6 levels and elevated CRP was also noted by this group 
(Takenawa a/, 1991).
Blay and co-workers proposed that IL-6 acts as an autocrine growth factor in vivo in 
RCC, and correlates well with serum CRP levels (Blay et al, 1994).
Both CRP and IL-6 have been shown to have prognostic significance in RCC, but 
whether one is superior as a prognostic indicator has yet to be examined, nor is their 
inter-relationship fully understood. The source of IL-6 secretion has also to be verified as 
it is often ascribed to the tumour itself, though circulating levels after nephrectomy have 
yet to be examined.
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1.12.3 Interleukin-10 and Renal Cancer
IL-10 was first described in 1989 as “cytokine synthesis inhibitory factor” 
(Fiorentino et al, 1991) and is produced by macrophages and T-helper 2 cells. IL-10 is a 
homodimer with a molecular mass of 37 kDa (Asadullah et al, 2003). The IL-10 gene is 
located on Chromosome 1 and codes for 5 exons. IL-10 is an inhibitory cytokine that 
suppresses the production of pro-inflammatory cytokines, Thl cytokine release and 
antigen presenting cells (see Fig 1.2).
1.12.3(i) IL-10 and advanced cancer
Elevated IL-10 serum concentrations in patients with metastatic RCC have been 
shown to be predictive of a poorer survival, median 11 months, in comparison to patients 
with low or undetectable IL-10, median survival 27 months (Wittke et al, 1999).
In contrast, Uwatoko and colleagues have demonstrated an association between absence 
of IL-10 expression and distant métastasés in RCC, suggesting a tumour inhibitory role 
for IL-10. However, circulating IL-10 concentrations were not quantified, and patients 
with bilateral, metastatic and primary tumours were included in their analysis (Uwatoko 
et al 2002).
1.12.3(ii) InterIeukin-10 and localised disease
In renal cancer, IL-10 mRNA is detectable in vivo, and RCC cell lines have been 
shown to induce IL-10 production by monocytes in vitro (Menetrier-Caux et al, 1999). 
Tumour infiltrating lymphocytes isolated from RCC have also been shown to express IL- 
10 mRNA (Maeurer et al, 1995). The role of IL-10 secretion in RCC, and its relationship 
with other cytokines such as IL-6 has not been fully explored. Elevated serum IL-10
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concentrations were associated with higher tumour stage, and elevated IL-6 in patients 
with colorectal cancer (Ordemann et al, 2002). In a small study elevated pre-operative IL- 
10 and IL-6 concentrations used in combination were also predictive for non-curative 
resection in colorectal cancer (Galizia et al, 2002). The relationship between IL-6 and IL- 
10 and CRP concentrations in patients with RCC has not been examined.
1.12.4 Immune Dysfunction
Historical clinical observations created early interest in the role of immune 
dysfunction in RCC. The rare event of regression of métastasés after nephrectomy has 
been recorded since 1928 (Kavoussi etal, 1986) and has prompted speculation over the 
role of immune mediation in metastatic regression. Similarly, the development of distant 
métastasés many years after nephrectomy has also led to suggestions that delayed failure 
of immune surveillance may be responsible.
To mount an active host anti-tumour immune response requires activation of T- 
lymphocytes in association with presentation of tumour antigen peptides on various 
antigen-presenting cells. T-lymphocytes produce two differing responses when 
stimulated. Type I (Th-1) responses generally act to stimulate cell-mediated immunity, 
characterised by the production of cytokines such as TNF, IL-2 and IFN-y; whilst Type II 
(Th-2) stimulate humoral immunity and the production of antibodies by B cells, 
characterised by cytokines IL-2, IL-4, IL-5, IL-6, and IL-10. There is cross-regulation 
between the two responses with IL-10 known to down-regulate the Type I response, 
whilst IFN-y and IL-2 reduce humoral immunity by down-regulating Th-2 cells and their 
cytokine production (Fiorentino et al, 1989).
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It is has been shown there is a shift from the usual balance of responses to a Type 
II bias, with a reduced level of circulating Thl cytokines in patients with solid tumours 
(Goto et al, 1999). It has been suggested that increasing tumour stage in RCC is 
associated with this shift to Th2 predominance, whilst mounting an effective cell- 
mediated anti tumour response requires a shift back to Thl cytokines (Derweesh et al, 
2003).
Examination of resected primary tumours has revealed the presence of a 
significant tumour infiltration by mononuclear cells, in particular T-lymphocytes and 
macrophages suggesting another important role for immune dysfunction in the 
pathogenesis of RCC. These tumour infiltrating lymphocytes (TILs) have been shown to 
be dysfunctional, with reduced cellular signalling and responsiveness, along with reduced 
antigen presenting capacity. A high TIL count is associated with higher stage tumours, 
increased necrosis and a higher pathological grade (Kolbeck et al, 1992).
The subsets of TILs have also demonstrated prognostic significance though 
results from different groups are conflicting. Bromwich and colleagues have 
demonstrated that a high TIL CD4-f- count is associated with a poorer disease-free 
survival in patients undergoing curative nephrectomy (Bromwich et al, 2003). In contrast, 
Nakano and co-workers have reported that a high intratumoral CDS-f- in RCC is 
prognostic for poorer outcome, and is associated with increasing tumour grade and 
proliferation (Nakano et al, 2001). These findings are in direct opposition to their 
findings in colorectal cancer where a high CD8-I- count predicts better prognosis (Naito et 
al, 1998). Igarashi and co-workers also reported an association between elevated TIL 
levels of CD84- and progressive disease in patients treated with interferon (Igarashi et al.
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2002). Interestingly, his research has also suggested an association between a raised 
CD8+ and raised CRP. It has been proposed that tumour secretion of IL-10 may play a 
role as IL-10 is chemo-attractant for CD8+ cells but suppresses IL-8 related migration in 
CD4-I- cells (Jinquan et al, 1993).
Examining circulating peripheral lymphocytes, it has been reported that a high 
proportion of CD8+ cells is predictive of increased recurrence after nephrectomy, and 
associated with progressive disease in patients with metastatic RCC treated with IFN 
(Arima et al, 1996). However, the role of CD4 lymphocytes as a predictive tool in 
patients with metastatic RCC treated with immunotherapy has yet to be examined. 
Similarly, there are no studies investigating the relationship between the systemic 
inflammatory response and immune dysfunction in metastatic RCC
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1.13 Hypothesis
A complex balance of pro-inflammatory and anti-inflammatory cytokines controls the 
systemic inflammatory response. It is hypothesized that the presence of a systemic 
inflammatory response, as evidenced by an elevated C-reactive protein concentration, is 
due to an imbalance between increased synthesis of pro-inflammatory cytokines such as 
IL-6, and subsequent increase of anti-inflammatory cytokines such as IL-10, leading to 
immune dysfunction and impaired Thl anti tumour response.
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1.14 Aims
• To evaluate the prognostic value of an inflammation based prognostic score in 
patients with metastatic renal cancer.
• To evaluate the prognostic role of an inflammation based prognostic score in 
patients with primary operable renal cancer.
• To examine the relationship between the systemic inflammatory response and a 
Thl/Th2 cytokine profile in patients with undergoing nephrectomy for renal 
cancer.
• To examine the longitudinal relationship between the systemic inflammatory 
response, circulating T-lymphocytes, interleukin-6 and interleukin-10 in patients 
with metastatic renal cancer treated with immunotherapy.
• To examine the longitudinal relationship between the systemic inflammatory 
response, interleukin-6 and interleukin-10 in patients undergoing nephrectomy for 
primary operable renal cancer.
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Figure 1.1 Changing pattern of acute phase proteins after a moderate inflammatory 
stimulus (Adapted from Gabay and Kushner, 1999).
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Table 1.1 Location of métastasés from primary renal cancer
Site of métastasés Single Site (%) Multiple Sites (%)
Lung 72 77
Soft Tissue 10 54
Bone 11 26
Liver 5.5 26
Central Nervous 
System
1.4 12
Skin 0 13
Other 0 7
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Table 1.2 Bosniak Classification of Renal Cysts
Class Description Nature
I Uncomplicated, simple Benign
II Minimally complicated, some findings to cause concern eg septae, 
hyper dense cysts
Benign
III More complicated -  irregular margins, thickened septae, thick 
irregular calcification
Uncertain
IV Large, cystic, irregular shaggy margins, areas of solid enhancing 
tissue
Malignant
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Table 1.3 Fuhrman System of Nuclear Grading
Grade Nuclear Size Nuclear Outline Nucleoli
1 10 mm Round, uniform Absent / inconspicuous
2 15 mm Irregular Small
3 20 mm Irregular Prominent
4 >20 mm Bizarre, multi-lobed Prominent, heavy chromatin
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Table 1.4 Robson Staging System
Stage Sub stage Description
I Confined to the kidney
II Perirenal fat involvement, but within Gerota’s fascia
III A Gross renal vein or inferior vena cava involvement
B Lymphatic involvement
C Vascular and lymphatic involvement
IV A Adjacent organs other than adrenal involved
B Distant métastasés
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Table 1.5 TNM Staging System 2001
TUM OUR
Tx Primary tumour cannot be assessed
TO No evidence of primary tumour
T la Tumour less than 4 cm, limited to the kidney
T lb Tumour greater than 4 cm, no greater than 7 cm, limited to the 
kidney
T2 Tumour greater than 7 in greatest dimension, limited to the 
kidney
T3 Tumour extends into major veins or perinephric fat but not 
beyond Gerota’s fascia,
T3a: Tumour invades perinephric tissues but not beyond 
Gerota’s fascia
T3b: Tumour grossly extends into renal vein(s) or vena cava 
below diaphragm
T3c; Tumour grossly extends into vena cava above diaphragm
T4 Tumour invades beyond Gerota’s fascia
NODES
Nx Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
NI Metastasis in a single regional lymph node
N2 Metastasis in more than one regional lymph node
METASTASES
Mx Distant métastasés cannot be assessed
MO No distant métastasés
M l Distant métastasés
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Table 1.5b: TNM Stage classification
Stage TNM
Stage 1 T1 NO MO
Stage 11 T2 NO MO
Stage 111 T1 N1 MO
T2 N1 MO
T3 NOT MO
Stage IV T4 NOT MO
Any T N2 MO
Any T Any N M l
Table 1.6 Five year survival according to TNM stage
Stage Robson Tsui Hermanek Storkel
1 66% 91% 91% 98
11 64% 74% 92% 93
111 42% 67% 64% 58
IV 11% 32% 15% 33
NB -  Robson cohort uses Robson staging system
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Table 1.7 ECOG Performance Status
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature eg light house work, office work
2 Ambulatory and capable of self-care but unable to carry out any work activités. 
Up and about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours
4 Completely disabled. Cannot carry on any self care. Totally confined to bed or 
chair
5 Dead
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2.0 Patient Study: Evaluation of an inflammation based prognostic score in 
patients with metastatic renal cancer.
2.1 Introduction
Renal cell cancer, although the 12* most common cause of cancer death is one of 
the most lethal urological cancers. Each year in the UK, there are approximately 3,500 
new cases and approximately 30% of patients present with métastasés, with a further 40% 
developing métastasés after a potentially curative resection (Cancer stats. Cancer 
Research UK).
As previously discussed in Chapter one, the mainstay of treatment in metastatic 
renal cancer is immunotherapy though in specific circumstances there is a role for surgery 
such as cytoreductive nephrectomy or metastasectomy. Whilst interferon-based 
immunotherapy has been shown to provide a consistent survival advantage in 4 
randomised placebo controlled trials, this is measured in months and is a toxic treatment 
with considerable side-effects (Steineck et al, 1990; Kriegmair eta l, 1995; Pyrhonen et 
al, 1999; MRC RCC et al, 1999).
There is increasing interest in improving selection of patients with good prognosis 
for more active treatment, and patients with poor prognosis for less active and less toxic 
treatment since this will improve overall patient outcomes. At present, performance status 
(Eastern Cooperative Oncology Group, ECOG-ps) is widely used as a prognostic tool in 
patients with metastatic disease. However, the assessment of performance status is 
subjective variable with significant inter-observer variability (Ando et al, 2001). For 
these factors to be clinically useful they should be routinely available, well standardized 
and validated in different patient cohorts.
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There is increasing evidence that the presence of a systemic inflammatory 
response, as evidenced by an elevated circulating C-reactive protein concentration or 
hypoalbuminaemia, is an independent prognostic factor in patients with advanced cancer 
(McMillan et al, 2001 ; Maltoni et al, 2005). With reference to renal cancer an elevated C- 
reactive protein has been shown to be associated with poorer cancer specific survival in 
patients with advanced disease (Atzpodien et al, 2003; Bromwich et al, 2004; 
Casamassima et al, 2005).
It is therefore of interest that the combination of hypoalbuminaemia and an elevated 
C-reactive protein, as in the Glasgow Prognostic Score (GPS), has been shown to 
provide additional prognostic information in patients with advanced cancer (Forrest et 
al, 2003; Forrest et al, 2004; Al-Murri et al, 2006; Crumley et al, 2006; Glen et al, 
2006).
A number of prognostic scoring systems are in use to stratify patients with metastatic 
renal cancer into risk groups (Motzer et al, 1999; Atzpodien et al, 2003). However, 
these systems incorporate a variety of different biochemical, histological and 
radiological features and it is not known how these scoring systems compare. 
Therefore, the aim of the present study was to examine the value of the GPS, in 
comparison with established scoring systems, in predicting cancer specific survival in 
patients with metastatic renal cancer
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2.2 Patients and Methods
Patients with metastatic renal cancer, who, on the basis of clinical findings and 
computed tomography of chest and abdomen were diagnosed with metastatic disease 
between 2001 and 2005 in the West of Scotland, and referred to the specialist renal 
cancer unit, were included in the study. The out-patient treatment regimes were either 
subcutaneous alpha-interferon given at 10 mega-units three times weekly on a 12-weekly 
basis, or a modified Atzpodien regime of subcutaneous alpha-interferon, subcutaneous 
interleukin-2 for five weeks, with an additional 3 weeks of 5-flourauracil given 
intravenously.
Patients who underwent surgery were staged pathologically according to the 1997 
UICC TNM classification of renal tumours (Sobin & Wittekind, 1997). Tumours were 
graded according to criteria set out by Fuhrman et al (1982) if biopsies or surgery had 
been performed. Clinical stage and performance status (Eastern Cooperative Oncology 
Group, ECOG-ps) were recorded prior to treatment initiation. Prior to commencement of 
treatment for métastasés routine laboratory measurements of lactate dehydrogenase, 
haemoglobin, calcium, differential white cell count, albumin and C-reactive protein were 
carried out.
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
The Memorial Sloan Kettering Cancer Centre (MSKCC) score was derived as 
previously described (Motzer et al, 1999). In this system an abnormal haemoglobin, 
calcium, lactate dehydrogenase three times greater than the upper limit of normal, 
Kamofsky performance status <80% and the absence of prior nephrectomy are
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considered as risk factors. Patients with no risk factors are classified as favourable, one to 
two as intermediate, and three or greater as poor risk.
The Metastatic Renal Carcinoma Comprehensive Prognostic System (MRCCPS) 
was scored as previously described (Atzpodien et al, 2003). Briefly, six pre-treatment 
variables are used to categorise patients into low, intermediate and high risk groups. 
Neutrophil count is given the highest weighting, the remainder of the factors are C- 
reactive protein greater than 10 mg/1, lactate dehydrogenase greater than 220 U/1, the 
presence of bone métastasés, and onset of metastatic disease of less than three years from 
diagnosis all assigned one point. Patients with zero or one point are low risk, two or three 
intermediate risk, and four or greater are classified as high risk.
The GPS was constructed as previously described (Forrest et al, 2003, 2004). In 
essence, patients with both an elevated C-reactive protein (>10 mg/1) and 
hypoalbuminaemia (<35g/l) were allocated a score of two. Patients in whom only one of 
these biochemical abnormalities was present were allocated a score of one. Patients in 
whom neither of these abnormalities was present were allocated a score of zero.
2.2.1: Statistics
Comparisons between groups of patients were carried out using contingency table 
analysis (X^) as appropriate.Grouping of the laboratory variables haemoglobin, white 
cell, lymphocyte counts, albumin and C-reactive protein was carried out using standard 
thresholds (O’Gorman et al, 2000; McMillan et al, 2001; Maltoni et al, 2005). Survival 
(cancer-specific) analysis of the group variables was performed using the Cox 
proportional hazard model. Deaths up to the end of July 2006 have been included in the
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 ^ analysis. Multivariate survival analysis, including all covariates that were significant on 
univariate analysis, was performed using a stepwise backward procedure to derive a final 
model of the variables that had a significant independent relationship with survival. To 
remove a variable from the model, the corresponding P-value had to be greater than 0.10. 
Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).
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2.3 Results
The characteristics of patients with metastatic renal cancer (n=l 19) are shown in 
Table 2.1. The majority were male and over the age of 60 years and had prior surgical 
treatment. The majority of patients had an ECOG performance status of 0 and had lactate 
dehydrogenase, calcium, white cell count, neutrophil count, percentage lymphocytes, and 
albumin measurements in the normal range. In contrast, the majority of patients had an 
elevated C-reactive protein concentration and of the 18 patients with hypoalbuminaemia 
15 (83%) had an elevated C-reactive protein concentration.
The minimum follow-up of patients was 5 months, the median follow-up of the 
survivors was 15 months. During this period 78 patients died of their cancer, and the 
median survival was eight months. On univariate survival analysis of individual 
variables, lactate dehydrogenase (p<0.10), haemoglobin (p<0.01), calcium (p<0.001), 
white cell count (p<0.01), neutrophil count (p<0.05), albumin (p<0.01) and C-reactive 
protein were significantly associated with cancer specific survival. On multivariate 
analysis of these significant factors only calcium (HR 3.21, 95%CI 1.51-6.83, p=0.002), 
white cell count (HR 1.66, 95%CI 1.17-2.35, p=0.004), albumin (HR2.63, 95%CI 1.38- 
5.03) and C-reactive protein (HR 2.85, 95%CI 1.49-5.45, p=0.002) were independently 
associated with cancer specific survival.
On univariate survival analysis of the scoring systems, the MSKCC (p<0.001. 
Figure 2.1), the MRCCPS (p<0.01. Figure 2.2), and the GPS (p<0.001. Figure 2.3) were 
significantly associated with cancer specific survival. On multivariate analysis of these 
scoring systems, the MSKCC (HR 1.88, 95%CI 1.22-2.88, p=0.004), the MRCCPS (HR
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1.42, 95%CI 0.97-2.09, p=0.071), and the GPS (HR 2.35, 95%CI 1.51-3.67, p<0.001) 
were independently associated with cancer specific survival.
The relationship between clinicopathological characteristics and an inflammation- 
based prognostic score (GPS) in patients with metastatic renal cancer is shown in Table 
2.2. An increasing GPS was associated with a lower haemoglobin (p<0.001), higher 
calcium (p<0.001), lower percentage lymphocytes (p<0.01) and greater risk of poor 
survival as estimated by the MSKCC and the MRCCPS scoring systems. The median 
survival in these patients was 28 months, 11 months and 3 months for a GPS of 0, 1 and 
2, respectively.
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2.4: Discussion
In the present study we have shown that the presence of a systemic inflammatory 
response, as evidenced by an elevated C-reactive protein concentration and 
hypoalbuminaemia, predicts cancer-specific survival, independent of other established 
prognostic factors such as performance status, calcium, lactate dehydrogenase and 
neutrophil counts in patients with metastatic renal cancer. Moreover, we have shown that 
the GPS compares favourably with MSKCC and is superior to the MRCCPS scoring 
systems.
At the time of diagnosis, there are well-established prognostic factors on which to 
base the prediction of likely survival in cancer patients. As a result, clinicians often 
overestimate survival (Glare, 2005). The results of the present study suggest that the GPS 
may be useful in the assessment of survival in patients with metastatic renal cancer. It is 
simple to use and based on routinely available, well standardized measurements. 
Therefore it may be that this simply derived inflammation-based score will be a useful 
tool in the prediction of survival and possible stratification, at diagnosis, of patients with 
metastatic renal cancer.
The mechanisms by which a systemic inflammatory response might influence 
cancer survival in these patients are not clear. However, it may be that the presence of a 
systemic inflammatory response and the associated nutritional decline (McMillan el al, 
1998; Scott et al, 2002) influences tolerance and compliance with active treatment 
(Bromwich et al, 2004; Forrest et al, 2004). It may also reflect the proinflammatory 
cytokine activity, in particular interleukin-6 (McKeown et al, 2004), which not only 
stimulates renal tumour growth (Trikha et al., 2003), but also produce profound catabolic
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effects on host metabolism (McMillan et al, 1998; Kotler, 2000). In this way, the 
presence and magnitude of a chronic systemic inflammatory response, as reflected by the 
GPS, may produce progressive nutritional and functional decline, ultimately resulting in 
reduced survival. Indeed, this concept is consistent with the observation in the present 
study that almost all patients with hypoalbuminemia had an elevated C-reactive protein 
concentration.
Due to the high toxicities and low response rates of immunotherapy, there has 
been considerable interest in the use of new targeted agents such as sorafenib and 
sunitinib in patients with metastatic renal cancer (Motzer et al, 2006). Early reports of 
increased progression-free survival, and more recently of increased overall survival may 
lead to these drugs being adopted as the first-line treatment. It remains to be established 
whether the GPS predicts which patients will benefit from these regimens.
In summary, the prognosis for patients diagnosed with metastatic renal cancer, 
even with active treatment, remains poor. The presence of a systemic inflammatory 
response (an elevated GPS) appears to be a useful indicator of outcome among these 
patients, independent of established scoring systems. Moreover, the GPS has the 
advantage of being simple to measure, routinely available and well standardised.
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Table 2.1 Clinicopathological characteristics and cancer specific survival in 
metastatic patients undergoing treatment for renal cancer. Univariate analysis
Age group (<60/>60 yrs)
Sex (male/ female)
ECOG-PS (0 /> l)
Lactate dehydrogenase (<300/ >300 U/1) 
Haemoglobin
(>13/ <13 g/dl M, >11.5/<11.5 g/dl F) 
Calcium (<2.5/ >2.5mmol/l)
Prior surgical treatment 
(curative/ cytoreductive/ none)
Disease free interval (>1/<1 year) 
Immunotherapy (Interferon/ Interferon, 
Interleukin-2, 5-FU)
Number of metastatic sites ( l/> 2 )
White cell count 
(<8.5/8.5-11.0/>11.0 10 /^1)
Neutrophil count (<6.5/ >6.5 10 /^1)
Lymphocyte percentage
(20 -40/ 12- 19.9/ 0 -1 1 .9  %)
Platelets (<400/ >400 10 /^1)
Albumin (>35/ <35g/l)
C-reactive protein (<10/ >10mg/l)
Patients 
(n= 119) 
56/64 
85/ 35 
93/ 26 
108/9
56/63 
100/19
48/ 22/ 50
35/ 35 
100/19
61/58
86/ 23/ 11 
92/27
58/47/ 15 
73/ 23 
103/ 16 
35/ 84
Hazard ratio p-value
(95%CI)
1.46 (0.93-2.30) 0.102
1.34 (0.84-2.15) 0.216
1.07 (0.62-1.86) 0.812
1.89 (0.90-3.96) 0.094
2.04(1.28-3.23) 0.003
3.67 (2.01-6.69) <0.001
0.85 (0.62-1.17) 0.328
0.96 (0.52-1.78) 0.897
0.96 (0.52-1.79) 0.910
0.83 (0.53-1.29) 0.402
1.56(1.13-2.15) 0.007
1.87(1.13-3.11) 0.015
1.30 (0.93-1.81) 0.122
3.71 (2.17-6.32) <0.001
2.52(1.38-4.61) 0.003
3.75 (2.02-6.97) <0.001
MSKCC (favourable/ intermediate/ poor) 31/ 72/ 13
MRCCPS (low/ intermediate/ high risk) 27/ 61/ 29
GPS (0/ 1/2) 28 /70/14
* Median (range)
2.44(1.60-3.70) <0.001
1.70(1.21-2.39) 0.002
3.03 (2 .01^.56) <0.001
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Table 2.2 The relationship between clinicopathological characteristics and an 
inflammation-based prognostic score (GPS) in patients with metastatic renal cancer.
GPSO GPS 1 GPS 2 p-value
(n= 33) (n=72) (n= 14)
Age group (<60/>60 yrs) 10/23 39/ 33 7 /7 0.074
Sex (male/ female) 23/10 51/21 10/4 0.892
ECOG-PS (0 /> l) 23/9 60/12 9 /5 0.990
Lactate dehydrogenase (<300/ >300 U/1) 31/2 66/ 4 11/3 0.165
Haemoglobin
(>13/ <13 g/dl M, >11.5/ <11.5 g/dl F) 25/8 28/44 3/11 <0.001
Calcium (<2.5/ >2.5mmol/l) 30/0 15/14 9 /5 0.001
Prior surgical treatment 
(curative/ cytoreductive/ none) 12/14/7 31 /32 /9 7 /2 /5 0.738
Disease free interval (>1/<1 year) 24/9 49/ 23 11/3 0.892
Immunotherapy (Interferon/ Interferon,
Interleukin-2, 5-FU) 26/7 64/8 10/4 0.989
Number of metastatic sites (1/ >2) 18/15 35/ 37 8 /6 0.938
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 2 7 /4 /2 50/15/ 7 9 /3 /2 0.162
Neutrophil count (<6.5/>6.5 10 /^1) 30/3 52/20 10/4 0.057
Lymphocyte percentage
(20 -40 / 12- 1 9 .9 /0 -1 1 .9  %) 20/ 12/0 31/30/11 6 /4 /4 0.009
MSKCC (favourable/ intermediate/ poor) 15/16/1 15/ 49 /6 1 /7 /6 <0.001
MRCCPS (low/ intermediate/ high risk) 16/14/3 10/38/ 22 1/ 9 /4 <0.001
Survival (months)* 28.3 (18.8-37.8) 10.7 (9.1-12.4) 3.4 (2.2-4.6) <0.001
*Median (range)
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Figure 2.1 Relationship between the MSKCC (favourable/ intermediate/ poor risk 
from top to bottom) and cancer-specific survival in patients with metastatic renal cancer.
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Figure 2.2 Relationship between the MRCCPS (low/ intermediate/ high risk from top 
to bottom) and cancer-specific survival in patients with metastatic renal cancer.
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Figure 2.3 Relationship between the GPS (0/ 1/ 2 from top to bottom) and cancer- 
specific survival in patients with metastatic renal cancer.
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3.0 Patient Study: The relationship between the systemic inflammatory 
response, prognostic scoring systems and cancer specific survival in patients 
undergoing potentially curative resection for renal cancer.
3.1 Introduction
As approximately 30% of patients who have undergone a curative nephrectomy 
will subsequently develop metastatic disease, there has been long-standing interest in 
identifying those patients most likely to die of renal cancer. Ideally, a factor or 
combination of factors would clearly stratify patients who will remain disease free and 
are “cured” from those who will ultimately die from their cancer. Currently TNM stage 
is the most widely used tool to predict likely outcome. However, despite revisions there is 
considerable “overlap” in survival between the stages. A number of cumulative 
prognostic scores, which include TNM stage and other host factors, have been developed 
to improve the prediction of survival in primary operable renal cancer. These include the 
combination of TNM stage, Fuhrman grade, and ECOG performance status (Eastern 
Cooperative Oncology Group) to form the UCLA Integrated Staging System (UISS, 
Zisman et al, 2002).
Recently, we have shown that the presence of a systemic inflammatory response, 
as evidenced by elevated circulating concentrations of C-reactive protein, provided 
additional prognostic value in patients with low and intermediate risk UISS scores 
undergoing potentially curative nephrectomy for renal cancer (Lamb et al, 2006). 
However, there are additional validated prognostic algorithms such as the SSIGN (Frank 
et al, 2003) and the Leibovich (Leibovich et al, 2002) scores.
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The aim of the present study was to examine the relationship between the 
systemic inflammatory response, prognostic scoring systems and cancer specific survival 
in patients undergoing potentially curative resection for renal cancer.
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3.2 Patients and Methods
Patients with renal cell carcinoma, who, on the basis of surgical findings and pre­
operative computerized tomography of the chest and abdomen underwent potentially 
curative resection between August 1996 and July 2005 in the North Glasgow NHS Trust 
were included in the study. No patient had T4 or metastatic disease, and all macroscopic 
tumour was removed at nephrectomy. The UISS score was derived as previously 
described (Zisman el al, 2002). Briefly, tumour stage, Fuhrman grade and ECOG 
performance status are combined to stratify patients into low, intermediate or high risk. 
Patients with high risk UISS scores were excluded.
Patients were staged pathologically according to the 1997 UICC TNM 
classification of renal tumours (Sobin & Wittekind 1997). Tumours were graded 
according to criteria set out by Fuhrman and co-workers (1982). Clinical stage and 
performance status (Eastern Cooperative Oncology Group, ECOG-ps) were recorded 
prior to surgery. Routine laboratory measurements including haemoglobin, white cell, 
neutrophil, lymphocyte, albumin and C-reactive protein were performed pre-operatively.
Data for 1996-2000 (n= 48) were collected retrospectively, and that for 2001- 
2005 (n= 63) prospectively. The Research Ethics Committee of North Glasgow NHS 
Trust approved the study.
3.2.1 Experimental design
The coefficient of variation for the routine laboratory measurements of 
haemoglobin, white cell, neutrophil and lymphocyte counts, albumin and C-reactive 
protein, over the range of measurement, was less than 10% as established by routine
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quality control procedures. The limit of detection of the assay was a C-reactive protein 
concentration lower than 6mg/l. A C-reactive protein concentration of greater than 
1 Omg/1 was considered to indicate the presence of systemic inflammatory response 
(O'Gorman et al, 2000; McMillan et al, 2001).
The SSIGN score was derived as previously described (Frank et al, 2002; Table 
3.1). Patients are awarded scores based on T stage, nodal disease, tumour size, nuclear 
grade, presence or absence of tumour necrosis and the presence or absence of métastasés 
(Table 3.1). The Leibovich score was derived as previously described (Leibovich et al, 
2002, Table 3.1). Patients are awarded scores based on T stage, nodal stage, tumour size,
I  nuclear grade, presence or absence of tumour necrosis (Table 3.1). The Leibovich score is
1 similar to the SSIGN score, though weighting of individual variables differs (Table 3.1).
i
I Patients with scores of zero to two were classified as low risk, three to five as
j
I intermediate, and six or greater as high risk.
I
I  3.2.2 Statistics
Comparisons between groups of patients were carried out using contingency table 
analysis (X^) as appropriate. Survival analysis was performed using the Cox’s 
proportional-hazards model. Deaths up to the end of August 2006 were included in the 
analysis. Multivariate survival analysis was performed using a stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival. To remove a variable from the model, the corresponding P- 
value had to be greater than 0.10. Analysis was performed using SPSS software (SPSS 
Inc., Chicago, IL, USA).
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3.3 Results
The characteristics of patients with renal cancer who underwent potentially 
curative resection (n= 111) are shown in Table 3.2. The majority were male, over the age 
of 60 years, had good performance status, had T stage 1/ II disease and absent tumour 
necrosis. The majority had haemoglobin, white cell, neutrophil and lymphocyte counts, 
albumin and C-reactive protein concentrations in the normal range. Of these parameters 
C-reactive protein was most commonly abnormal (37%).
The minimum follow-up was 14 months; the median follow-up of the survivors 
was 47 months. During this period 28 patients died; 20 patients of their cancer and eight 
of intercurrent disease. On univariate survival analysis, tumour stage (p<0.001), Fuhrman 
grade (p<0.01), tumour necrosis (p<0.001), haemoglobin (p<0.01), C-reactive protein 
(p<0.01), SSIGN (p<0.001) and Leibovich (p<0.001) scores were significant predictors 
of cancer specific survival. On multivariate analysis with haemoglobin, C-reactive 
protein, SIGN and Leibovich entered as covariates, only C-reactive protein (HR 2.69, 
95% Cl 1.00-7.23, p=0.050) and Leibovich (HR 4.44, 95% Cl 1.91-10.28, p<0.001) 
were significant independent predictors of cancer-specific survival.
The preoperative values of C-reactive protein at the thresholds of greater than 
five, and greater than ten mg/1 were compared in multivariate survival analysis. In this 
analysis, the prognostic significance of the ten mg/1 (p=0.003) was greater than the five 
mg/1 (p=0.110).
The relationship between the presence of a systemic inflammatory response and 
the clinicopathological characteristics are shown in Table 3.3. There was no significant
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difference in age or sex between the inflammatory and non-inflammatory groups. An 
elevated C-reactive protein was associated with a greater number of patients with 
advanced tumour stage (p<0.001), lower haemoglobin (p<0.001) and poor UISS 
(p<0.01), SIGN (p<0.001) and Leibovich scores (p<0.001).
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3.4 Discussion
The present study evaluated the prognostic value of the systemic inflammatory 
response and compared, for the first time, a number of prognostic scoring systems in 
patients undergoing potentially curative resection for colorectal cancer. From this 
comparison it is clear that, in the present cohort, that the Leibovich algorithm is superior 
to the others and that an elevated C-reactive protein provides additional prognostic value.
In the present study the patients studied were either low or intermediate risk as 
defined by the UISS criteria (tumour stage, Fuhrman grade and performance status) and 
patient survival was not significantly different between these risk groups. In contrast, 
increasing SSIGN and Leibovich and scores derived from additional criteria (tumour size 
and tumour necrosis) were significantly associated with poor cancer specific survival. 
These results would suggest that such additional criteria, in particular tumour necrosis, 
are of considerable prognostic value in patients undergoing potentially curative resection 
for renal cancer.
In the present study although SSIGN and Leibovich scores were derived using 
similar criteria, on multivariate analysis the Leibovich score appeared to be superior in 
predicting cancer specific survival. This may have been due to the fact that tumour stage 
was more highly scored compared with that of the SSIGN score. This may be related to 
the SSIGN score having been developed in a group of patients which included patients 
who had proven metastatic disease, whereas the Leibovich score was developed from a 
cohort of patients without evidence of metastatic disease.
We have previously reported that an elevated C-reactive protein had additional 
prognostic value to that of the UISS score (Lamb et al, 2006). In the present study we
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were able to confirm this finding and also establish that an elevated C-reactive protein 
had additional prognostic value to the SSIGN and Leibovich scores. An elevated C- 
reactive protein concentration has recently been incorporated into a prognostic score for 
patients with metastatic renal cancer (Atzpodien et al, 2003; Royston et al, 2006), and the 
previous chapter has reported the prognostic value of a cumulative inflammation based 
score (GPS). Given this, the results of the present and previous studies (Masuda et al, 
1998; Lamb et al, 2006) would support the inclusion of C-reactive protein concentrations 
into prognostic scoring systems for patients with primary operable renal cancer. Of 
interest, hypoalbuminaemia appears to be a rare event in patients with operable renal 
cancer, and as such the GPS could not be applied to this cohort.
It was of interest that the threshold for C-reactive protein (>10 mg/1) which was 
originally established in studies of patients with gastrointestinal cancer (O’Gorman et al, 
2000) and subsequently verified in patients with renal cancer (Bromwich et al, 2004) was 
superior to that (>5 mg/1) used recently in a similar study of patients with operable renal 
cancer (Komai et al, 2006).
This is a relatively small study in a single centre and requires verification in large 
cohorts in other centres. If an elevated C-reactive protein concentration is confirmed to 
predict a poorer prognosis, decision making regarding radical nephrectomy in patients 
with extensive co-morbidity, or those with high-risk locally advanced tumours, may be 
influenced by the presence of a high inflammatory profile pre-operatively. Alternatively, 
modulation of the systemic inflammatory response may be a useful approach in these 
patients in the pre-operative period. In summary, the results of the present study indicate 
that in patients selected to undergo potentially curative resection for renal cancer, the
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I presence of an elevated C-reactive protein concentration pre-operatively (>1 Omg/1) is an 
independent predictor of poor cancer-specific survival.
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Table 3.1 SSIGN and Leibovich scoring algorithms
Feature 
T Stage: pT la 
pTlb 
pT2 
pT3a 
pT3b 
pT3c 
pT4
Nuclear grade:
1
2
3
4
N Stage: pNx/ 
pNO 
pN l/2 
Tumour size <5 cm 
>5cm
Histologie tumour necrosis: 
Absent 
Present 
M Stage: pMO 
pM l
SSIGN score Feature Leibovich Score
T Stage: p T la  0
pT lb  2
pT2 3
pT3a 4
pT3b 4
pT3c 4
pT4 4
Nuclear grade:
1 0
2 0
3 1
4 3
N Stage: pNx/ 0
pNO 0
pN l/2 2
<10 cm 0
>10 cm 1
Absent 0
Present 1
Table 3.2 Baseline characteristics and cancer specific survival in patients undergoing 
potentially curative nephrectomy. Univariate analysis
Patients 
( n = l l l )
UISS (low/ intermediate risk) 29/ 82
Age group (<60/>60 yrs) 47/ 64
Sex (male/ female) 67/ 44
E C O G PS(0/>1) 93/18
T Stage (1/ II/ III) 51/22/38
Fuhrman Grade (1/ 2/ 3/ 4) 20/ 46/ 34/11
Tumour necrosis (Absent/ present) 73/ 38
Haemoglobin
(M>13/ <13 g/dl, F ^l 1.5/ <11.5 g/dl) 80/ 24
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 85 /12 /7
Neutrophil count (<6.5/ >6.5 10 /^1) 92/ 9
Percentage total lymphocytes
(20-40/ 12.0-19.9/ 0-11.9 %) 76/ 20/ 5
Albumin (>35/ <35 g/1) 108/1
C-reactive protein (<10/ >10 mg/1) 70/41
SIGN (0-3/ 4-6/ >7) 56/ 40/ 15
Leibovich score (low/ intermediate/ high) 39/ 50/ 22
Hazard ratio p-value
(95%CI)
3.06 (0.71-13.31) 0.135
0.93 (0.38-2.26) 0.868
1.26 (0.52-3.03) 0.613
1.03 (0.34-3.08) 0.965
2.99(1.52-5.85) 0.001
2.06 (1.22-3.48) 0.007
4.76(1.89-11.98) <0.001
4.19(1.52-11.56) 0.006
0.99 (0.45-2.16) 0.971
0.76 (0.10-5.84) 0.794
1.60 (0.68-3.77) 0.278
0.841
4.39(1.69-11.44) 0.003
3.73 (2.03-6.85) <0.001
4.94 (2.26-10.79) <0.001
89
Table 3.3 The relationship between the presence of a systemic inflammatory 
response and clinicopathological characteristics in patients with operable renal cancer.
C-reactive protein C-reactive protein p-value
(<10 mg/1, n= 70) (>10 mg/1, n=41)
UISS (low/ intermediate risk) 25/45 4/37 0.003
Age group (<60/>60 yrs) 33/ 37 14/27 0.183
Sex (male/ female) 44/26 23/18 0.484
ECOG-PS (0 /> l) 61/9 32/9 0.212
T Stage (1/11/ III) 41/12/ 17 10/10/21 <0.001
Fuhrman Grade (1 /2 /3 /4 ) 13/ 32 /21 /4 7/ 14/13/7 0.137
Tumour necrosis (Absent/present) 50/20 23/ 18 0.102
Haemoglobin
(>13/ <13 g/dl M, >11.5/ <11.5 g/dl F) 58/8 22/ 16 0.001
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 5 6 /6 /4 29/ 6/ 3 0.372
Neutrophil count (<6.5/>6.5 10 /^1) 60/4 32/5 0.219
Percentage total lymphocytes
(20-40/ 12.0-19.9/ 0-11.9%) 50 /10 /4 26/ 10/ 1 0.708
Albumin (>35/ <35 g/1) 68/1 40 /0 0.446
SIGN (0-3/4-6/>7) 44 /21 /5 12/19/10 <0.001
Leibovich score (low/ intermediate/ high) 32 /29 /9 7 /21 / 13 0.001
Survival (months) 97.2 (89.3-105.1) 81.5 (58.6-104.4) <0.001
Mean (95% Cl)
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Fig 3.1 Relationship between the Leibovich score (favourable/ intermediate/ poor
risk from top to bottom) and cancer-specific survival in patients with operable renal 
cancer
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Fig 3.2 Relationship between C-reactive protein concentrations (<10 mg/1 / >10 
mg/1 from top to bottom) and cancer-specific survival in patients with operable renal
cancer
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4. 0_______Patient study: The relationship between the systemic inflammatory
response and Thl/Th2 cytokines in patients with primary operable renal cancer.
4.1 Introduction
It is increasingly recognised that, in addition to recognised risk factors such as 
tumour stage and grade, disease recurrence and subsequent outcome depends on a 
complex interaction of the tumour and host inflammatory response (Balkwill & 
Mantovani, 2001 ; Coussens & Werb, 2002; Vakkila & Lotze, 2004)). In Chapter two 
we have shown that the systemic inflammatory response, as evidenced by circulating 
concentrations of C-reactive protein and hypoalbuminaemia, the GPS, had prognostic 
value independent of the MSKCC score (Motzer et al, 1999) in patients with 
metastatic renal cancer. In Chapter three, C-reactive protein, in addition to the 
Leibovich score (Leibovich et al, 2003) was associated with poorer cancer specific 
survival in patients with primary operable renal cancer.
It is now recognised that elevated circulating concentrations of C-reactive protein 
reflect the net effect of hormones and cytokines (Gabay & Kushner, 1999). To date, 
few studies have examined the cytokine profile associated with an elevated C-reactive 
protein in patients with cancer (McKeown et al, 2004) and to our knowledge none in 
renal cancer. Such profiles may be useful in identifying the underlying immune cell 
activation that may result in the elaboration of CRP.
It is of interest that tumour infiltration by T-lymphocytes has been reported to 
have prognostic significance in patients with renal cancer. Nakano and co-workers 
(2001) reported an association between increased intra-tumoral CD8+ T-lymphocytes
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and reduced cancer specific survival. In contrast, Bromwich and colleagues (2003) 
found no association between CD8+ T-lymphocytes and poor prognosis; though there 
was an association between increased CD4+ T-lymphocytes and reduced cancer 
specific survival.
Activation and suppression of Tl-lymphcyte function is tightly regulated by 
circulating cytokines. Type I (Th-1) responses generally act to stimulate cell-mediated 
immunity, characterised by the production of cytokines such as Tumour Necrosis 
Factor (TNF), IL-2 and IFN-y: Type II (Th-2) stimulate humoral immunity and the 
production of antibodies by B cells, characterised by cytokines IL-4, IL-5, IL-6, IL- 
10. There is a cross regulation between the two responses with IL-10 known to down- 
regulate the Type I response, whilst IFN-y and IL-2 down-regulate Th-2 cells and 
their cytokine production (Fiorentino et al, 1989). A Th-2 bias, with a reduced level 
of circulating Th-1 cytokines has been reported in a number of solid tumours 
including renal cancer (Rayman et al, 2004).
The aim of the present study was to examine the relationship between circulating 
concentrations of CRP and cytokines produced by the T-lymphocyte subset 
populations in patients with renal cancer.
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4.2 Patients and Methods
Patients with primary operable renal cancer, who underwent nephrectomy 
between March 2003 and October 2005 in the North Glasgow NHS Trust were included 
in the study. Patients were staged pathologically according to the 1997 UICC TNM 
classification of renal tumours (Sobin & Wittekind,1997).Tumours were graded 
according to criteria set out by Fuhrman and coworkers (1982). Clinical stage and 
performance status (Eastern Cooperative Oncology Group, ECOG-ps) were recorded 
prior to surgery.
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
4.2.1 Experimental design
I
I  A blood sample was collected prior to resection for routine laboratory analysis
I including C-reactive protein quantification. A further pre-operative sample of blood was
I
: drawn, centrifuged at 5,000 rpm for 8 minutes before aliquots of serum were snap frozenI
I  and stored at -80°C.
[
I The limit of detection of the assay for C-reactive protein was 6mg/l. The
I
coefficient of variation, over the range of measurement was less than 5% as established 
by routine quality control procedures. A C-reactive protein measurement of greater than 
■ lOmg/dl was considered to indicate the presence of a systemic inflammatory response 
(O’Gorman et al, 2000; Maltoni et al, 2005).
From a single serum sample (50[xl) IFN-y, IL-2, IL-4, IL-5 and IL-10 were measured 
using Luminex multi analyte profiling technology. Luminex technology utilises patented 
pre-dyed fluorescent microspheres occupying different regions of the optical spectrum.
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allowing up to one hundred analytes to be measured simultaneously in a single microtitre 
well. Briefly, an individual bead set is coated with a capture antibody for the analyte (in 
this case a cytokine) of choice. Combinations of these bead sets are then incubated with 
the sample, and after washing, further incubated with a cocktail of detection antibodies. 
Further washing is performed to remove any unbound antibodies. Finally, incubation with 
a fluorochrome is performed, to produce a sample-antibody-indicator sandwich, in a 
similar fashion to a conventional sandwich ELISA. Detection of beads and quantification 
of analytes was performed using a Multiplex system and Bio-plex software with five- 
parametric curve fitting (Bio-Rad, California, USA). In the present study, the analysis 
was carried out as per the manufacturer’s instruction using a preconfigured multiplex 
cytokine kit. (Biosource, California, USA). According to the product data sheet, the 
minimum detectable concentration for IFN-y was less than five pg/ml, IL-2 less than six 
pg/ml, IL-4 less than five pg/ml, IL-5 less than three pg/ml, and IL-10 less than five 
pg/ml.
From a single serum sample (200pl) IL-10 was measured using ELISA 
technology (RnD systems, Abingdon, UK). In summary, a monoclonal antibody specific 
for IL-10 is pre-coated onto a microplate. Any IL-10 in the sample added to each 
micro well is bound, and unbound substances removed by washing. Subsequently, an 
enzyme-linked polyclonal antibody specific for IL-10 is added to the wells. Following 
further washing, a substrate solution is added, and colour develops in proportion to the 
IL-10 bound initially. The colour changes are visible to the naked eye, but are read by an 
optical platemeter.
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4. 2. 2 Statistical Analysis
Data are presented as median and range. Cytokine concentrations below the 
threshold of sensitivity were expressed as equal to this threshold. Where appropriate, data 
were tested for statistical significance using the Mann-Whitney U test. Analysis was 
performed using SPSS software (SPSS Inc, Chicago, IL, USA).
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4.3 Results
The clinicopathological characteristics and cytokine concentrations of patients 
undergoing nephrectomy (n=53) grouped according to the presence or absence of a 
systemic inflammatory response are shown in Table 4.1. Age, gender and Furhman grade 
were similar between both groups. However, T-stage was significantly higher in the 
inflammatory group (p<0.05) and there were significantly more cytoreductive 
nephrectomies in the inflammatory compared with the non-inflammatory group 
(p<0.005). In those cytokines measured using the Luminex technology the circulating 
concentrations of IFN-y (p<0.01), IL-2 (p<0.005), IL-4 (p<0.005) and IL-5 (p<0.005) 
were significantly higher in the inflammatory group.
The inter-relationships between C-reactive protein, IFN-y, IL-2, IL-4, IL-5 and IL-10 are 
shown in Table 4.2. C-reactive protein was correlated with IFN-y (p<0.001), IL-2 
(p<0.01), IL-4 (p<0.001), IL-5 (p<0.001) and IL-10 (p<0.001). IFN-y, IL-2, IL-4, IL-5 
and IL-10 were all highly correlated with each other (rs>0.75, p<0.001).
Circulating concentrations of IL-10 measured using the ELISA technique were 
significantly higher in the inflammatory group (p<0.001). When the IL-concnetrations 
measured using the ELISA technique were compared with those measured with the 
Luminex technology, IL-10 concentrations were significantly higher in the later 
(p<0.001) The Luminex IL-10 and ELISA IL-10 concentrations were weakly, but 
significantly correlated (rs=0.37, p=0.003) and ELISA 11-10 concentrations were more 
significantly correlated with C-reactive protein (rg=0.75, p<0.001).
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4.4 Discussion
It is well recognised cytokines are secreted by and are regulators of immune 
system and the systemic inflammatory response. Furthermore, different cytokine 
functions are complex and overlapping and therefore the analysis of multiple related 
cytokines may be more informative with regard to their source than the measurement of a 
single cytokine. In the present study we examined the circulating concentrations of those 
cytokines recognised to have a role in T-lymphocyte function.
In the present study circulating concentrations of IFN-y, IL-2, IL-4, IL-5 and IL- 
10 measured by the Luminex technology were increased in those patients with evidence 
of a systemic inflammatory response. Also, IL-10 concentrations measured by the ELISA 
technique were increased in patients with evidence of a systemic inflammatory response. 
However, the ELISA values for IL-10 were lower, showed a lesser degree of variation, 
and were more significantly correlated with C-reactive protein when compared with IL- 
10 concentrations measured by the Luminex technology. The Luminex values for the 
other cytokines analysed showed similar variation to that of 11  ^10 measured by this 
approach.
Taken together the results of the present study would suggest firstly that the 
Luminex values are more variable and potentially less accurate compared with the more 
established ELISA technique. Secondly, that the systemic inflammatory response is 
associated with increased circulating concentrations of a variety of cytokines associated 
with both Th-1 and Th-2 responses.
The reasons for the wide range of values obtained using the Luminex technology 
are not clear. The method relies on the use of a filter mesh to suspend the beads and allow
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effective washing to remove residual unbound compounds. If the filter mesh had become 
clogged with particulate matter prior to wash cycles unbound cytokines may have 
remained in the wells prior to analysis. However the filter wells were not macroscopically 
clogged during the experiment. To date, multiplex analysis of cytokines has been almost 
exclusively limited to cell culture supernatants. In terms of the number of peptides and 
proteins such supernatants are much less complex than that of a plasma or serum sample. 
Indeed, the problems of analysing plasma or serum samples have been suggested by De 
Jager and colleagues (2003) who note that when sera are used as the analytical matrix the 
matrix should be carefully monitored for blocking substances such as heterophilic 
antibodies. Taken together the above observations would suggest that there is a need to 
pre-treat plasma or serum samples prior to multiplex analysis of cytokines.
In summary, there remain a number of technical challenges to be overcome before 
multiple cytokine analysis can be applied to identify the nature of the immune response 
and relationship to the systemic inflammatory response in patients with renal cell 
carcinoma. However, IL-10 concentrations measured with the ELISA technique were 
strongly correlated with C-reactive protein and worthy of further investigation.
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Table 4.1 Clinicopathological characteristics and cytokine profile according to the 
presence of absence of a systemic inflammatory response in patients with undergoing 
nephrectomy for renal cancer
C-reactive protein C-reactive protein p-valu
<1 Omg/1 (n=26) >1 Omg/1 (n=27)
Age (<60/ >60 years) 14/12 17/10 0.505
Gender (male/ female) 17/9 17/10 0.856
Curative/ 25/1 20/7 0.026
Cytoreductive
Stage 1/11/ III/ IV 16 /1 /8 /1 7/ 2/ 9/ 9 0.004
Grade 1/ 2/ 3/ 4 4/ 8/ 7/ 3 2 /5 /1 1 /6 0.176
Luminex measurement
IFN gamma (pg/ml) 474(15-14514) 770(115-1803) 0.010
IL-2 (pg/ml) 56 (6-655) 273 (8-1107) 0.003
IL-4 (pg/ml) 56 (5-356) 195 (12-551) 0.003
IL-5 (pg/ml) 43 (3-249) 141 (3-382) 0.002
IL-10 (pg/ml) 25 (5-2954) 62 (5-256) 0.058
ELISA measurement
IL-10 (pg/ml) 3.80 (3.80-9.66) 7.55 (3.80-23.62) <0.001
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Table 4.2 The inter-relationships between C-reactive protein and T-lymphocyte
cytokine profile in patients with renal cancer.
IFN Y (pg/ml) IL-2 (pg/ml) IL-4 (pg/ml) IL-5 (pg/ml) IL-10 (pg/ml)
rs (p-value) rs (p-value) rs (p-value) rs (p-value) rs (p-value)
C-reactive protein 0.54 (<0.001) 0.56 (<0.001) 0.53 (<0.001) 0.57 (<0.001) 0.43 (0.001)
(mg/1)
IFN Y (pg/ml) 0.84 (<0.001) 0.85 (<0.001) 0.87 (<0.001) 0.80 (<0.001)
IL-2 (pg/ml) 0.84 (<0.001) 0.97 (<0.001) 0.97 (<0.001 ) 0.75 (<0.001)
IL-4 (pg/ml) 0.85 (<0.001) 0.97 (<0.001) 0.99 (<0.001) 0.71 (<0.001 )
IL-5 (pg/ml) 0.89 (<0.001) 0.97 (<0.001) 0.99 (<0.001) 0.73 (<0.001
IL-10 (pg/ml) 0.80 (<0.001) 0.75 (<0.001) 0.71 (<0.001) 0.73 (<0.001 )
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5.0 Patient Study: The longitudinal relationship between the systemic 
inflammatory response, interleukin-6, interleukin-10 and circulating T-lvmphocvtes 
in patients undergoing immunotherapy for metastatic renal cancer.
5.1 Introduction
In the second chapter, we reported the prognostic significance of the systemic 
inflammatory response, as evidenced by the GPS, in patients with metastatic renal cancer 
treated with immunotherapy. However, the basis of the independent relationship between 
elevated C-reactive protein concentrations, poor response rates and poor survival in 
patients with metastatic renal cancer is not clear. One explanation is that an elevated C- 
reactive protein identifies an impaired T-lymphocytic response (Berczi et al, 2000) to the 
tumour (Maccio et al, 1998; Canna et al, 2005). If this were the case then it might be 
expected that circulating concentrations of interleukin-6 and interleukin-10, key 
mediators of T-lymphocyte stimulation and suppression respectively (Gabay & Kushner, 
1999; Jee et al, 2001; Trikha et al, 2003; Mocellin et al, 2005), would be abnormal. 
Indeed, in the previous Chapter we reported increased concentrations of various 
cytokines, but in particular a correlation between IL-10 and C-reactive protein. 
Interleukin-6 has been previously used as an indicator of the systemic inflammatory 
response and prognostic factor in patients with metastatic renal cancer (Blay et al, 1993), 
and is thought to be responsible for around 50% of C-reactive protein secretion in vivo 
(Gabay & Kushner, 1999). To our knowledge the longitudinal relationships between 
these inflammatory markers and T-lymphocytes have not been previously examined in 
patients undergoing immunotherapy for renal cancer.
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The aim of the present study was to examine the longitudinal relationship between 
C-reactive protein, interleukin-6, interleukin-10, and circulating T-lymphocyte sub­
populations in patients undergoing alpha-interferon-based immunotherapy for metastatic 
renal cancer.
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5.2 Patients and Methods
Patients with metastatic renal cancer who were immunotherapy naive and due to 
commence out-patient immunotherapy between May 2005 and February 2006 were 
included in the study. The out-patient regimes were either subcutaneous alpha-interferon 
given at 10 mega-units three times weekly on a 12-weekly basis, or a modified Atzpodien 
regime of subcutaneous alpha-interferon, subcutaneous interleukin-2 for five weeks, with 
an additional 3 weeks of 5-flourauracil given intravenously, both defined as one cycle. 
Patients were staged pathologically according to the 1997 UICC TNM classification of 
renal tumours (Sobin & Wittekind, 1997). Tumours were graded according to criteria set 
out by Fuhrman and coworkers (1982). Clinical stage and performance status (Eastern 
Cooperative Oncology Group, ECOG-ps) were recorded prior to treatment initiation 
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
5.2.1 Experimental design
A blood sample was collected, prior to initiation of immunotherapy, for routine 
laboratory analysis of haemoglobin, white cell count, lactate dehydrogenase, lymphocyte 
count, albumin and C-reactive protein. The limit of detection of the assay was a C- 
reactive protein concentration lower than 6mg/l. The coefficients of variation of these 
methods, over the range of measurements, was less than 10% as established by routine 
quality control procedures.
A further blood sample was taken, centrifuged, and the serum stored at -80°C 
prior to analysis of interleukin-6 and interleukin-10. Circulating concentrations of these
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cytokines were measured using an enzyme linked immunosorbent assay (ELISA) 
technique. The minimum detectable concentrations were 2 pg/ml for interleukin-6 and 
4pg/ml for interleukin-10 (Quantikine ELISA, R&D Systems Europe Ltd, Abingdon,
UK). Inter- and intra-assay variability was less than 10% for both assays. Cytokine 
concentrations below the threshold of sensitivity of the respective assays were expressed 
as equal to this threshold.
The blood sampling and analyses were repeated two to four weeks after 
commencing treatment at the first outpatient review. Performance status was recorded, 
along with any dose reductions or treatment breaks. CT scanning was performed after 
approximately eight to twelve weeks of immunotherapy to assess for disease response or 
progression.
The GPS was constructed as previously described (Forrest et al, 2003, 2004). 
Briefly, patients with both an elevated C-reactive protein (>10 mg/1) and 
hypoalbuminaemia (<35g/l) were allocated a score of two. Patients in whom only one of 
these biochemical abnormalities was present were allocated a score of one. Patients in 
whom neither of these abnormalities was present were allocated a score of zero.
The MSKCC scoring system (Motzer et al, 1999) was used to stratify patients into 
favourable, intermediate and poor risk groups. In this system an abnormal haemoglobin, 
calcium, LDH three times greater than the upper limit of normal, Kamofsky performance 
stautus <80% and the absence of prior nephrectomy are considered as risk factors.
Patients with no risk factors are classified as favourable, one to two as intermediate, and 
three or greater as poor risk.
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5.2.2 Statistics
Data are presented as median and range. Comparisons between groups of patients 
were carried out using contingency table analysis (X^) as appropriate. Grouping of the 
laboratory variables haemoglobin, white cell and lymphocyte counts and lactate 
dehydrogenase was carried out using standard thresholds (Maltoni et al, 2005). Where 
appropriate, data were tested for statistical significance using Mann-Whitney U test and 
the Wilcoxon signed rank test. As the distribution of C-reactive protein and the cytokines 
were skewed, they were logarithmically transformed prior to stepwise multiple regression 
analysis for the examination of independent associations with C-reactive protein. Survival 
(cancer-specific) analysis of the group variables was performed using the Cox 
proportional hazard model. Deaths up to the end of August 2006 were included in the 
analysis. Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).
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5.3 Results
The characteristics of patients with advanced renal cancer receiving alpha- 
interferon immunotherapy (n=23) are shown in Table 5.1. The majority were male and 
over the age of 60 years and had prior curative surgery. All patients had an ECOG 
performance status of less than or equal to one, haemoglobin and adjusted calcium in the 
normal range and a favourable or intermediate MSKCC risk. The majority of patients had 
lactate dehydrogenase, albumin, C-reactive protein, white cell and lymphocyte counts in 
the normal range. In contrast, the majority of patients had an elevated GPS, interleukin-6 
and interleukin-10. Of the seven patients with hypoalbuminaemia six (86%) had an 
elevated C-reactive protein concentration.
The patients were grouped according to whether or not the patients completed one 
cycle of treatment with no dose reduction of their immunotherapy regimen (Table 5.2). 
The patients who completed one cycle of immunotherapy were more likely to have a 
normal haemoglobin (p<0.01) and a favourable MSKCC score (p<0.05). In contrast, 
patients who did not complete one cycle of immunotherapy were more likely to have 
hypoalbumaemia (p<0.05), an elevated GPS (p<0.05) and a low percentage lymphocytes 
(p<0.05). There was a trend towards a higher interleukin-6 concentration (p<0.10).
The relationship between baseline clinicopathological criteria and cancer specific 
survival of patients with advanced renal cancer receiving immunotherapy (n=23) are 
shown in Table 5.2. The minimum follow-up was four months and nine (39%) patients 
died during the follow-up period. On univariate survival analysis, MSKCC (p<0.01), the 
GPS (p<0.01), interleukin-6 (p<0.05) and interleukin-10 (p<0.05) were significantly 
associated with poorer survival. On multivariate analysis of these significant factors only
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the MSKCC (HR 3.31, 95%CI 0.87-12.68, p=0.080) and the GPS (HR 3.15, 95%CI 0.88- 
11.24, p=0.077) were independently associated with cancer specific survival.
The before and after values of those patients completing one cycle of treatment 
are shown in Table 5.3. ECOG-ps, haemoglobin, adjusted calcium, MSKCC, lactate 
dehydrogenase, albumin, C-reactive protein, the GPS, white cell and lymphocyte counts 
and iterleukin-6 did not change significantly. In contrast, concentrations of interleukin- 
10 increased from pre-treatment values when measured at two weeks(p<0.01).
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5.4 Discussion
In the present prospective study of patients undergoing immunotherapy for 
metastatic renal cancer the failure to complete immunotherapy and poor cancer specific 
survival was significantly associated with the MSKCC risk classification and the 
systemic inflammatory response, as evidenced by the GPS. Both these prognostic scores 
were also associated with cancer specific survival and did not alter following one cycle of 
immunotherapy. These results confirm the importance of the MSKCC classification and 
the systemic inflammatory response in predicting the outcomes for patients with 
metastatic renal cancer treated with immunotherapy (Motzer et al, 2004; Bromwich et al, 
2004).
In contrast, the proportions of CD4+ and CD8+ T-lymphocytes were not 
significantly associated with the failure to complete immunotherapy, cancer specific 
survival and were not significantly altered during immunotherapy. These results would 
suggest that an impaired T-lymphocytic response is not a major factor in the failure of 
immunotherapy in these patients. Few studies have examined the role of circulating T- 
lymphocytes in immunotherapy treatment. One study of 25 patients treated with 
interferon suggested an elevated CD8+ T lymphocyte count was associated with reduced 
survival (Arima et al, 1996). However, this study has used arbitrary criteria to subdivide 
the patients, and multivariate analysis was not performed on the results derived from the 
patients treated with interferon.
In the present study there was a trend towards a higher interleukin-6 being 
associated with the failure to complete immunotherapy, poorer cancer specific survival 
and interleukin-6 concentrations were not altered following immunotherapy. However,
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compared with the MSKCC and the GPS classifications the value of interleukin-6 in 
predicting the response to immunotherapy appears limited. Therefore, these results do not 
confirm a major role for interleukin-6, proposed by Negrier and coworkers (2004), in 
determining treatment for patients with metastatic renal cancer.
It was of interest that, following immunotherapy, circulating concentrations of 
interleukin-10 were significantly increased. It has previously been reported that 
concentrations of interleukin-10 are progressively increased during treatment with high- 
dose interleukin-2 (Engelhardt et al, 1997). The basis of the increase in interleukin-10 
concentrations is not clear. However, as the proportions of T-lymphocytes before and 
during immunotherapy did not change significantly, this would suggest a source of 
interleukin-10 secretion other than the T-lymphocytes. Since C-reactive protein is known 
to activate macrophages (Du Clos & Mold, 2004) it may be that macrophages are a major 
source of interleukin-10 (Moore et al, 2001). Nevertheless, the results of the present 
study do not confirm a predictive role for interleukin-10 as proposed by Wittke and 
coworkers (1999). Therefore, it may be that the increase in interleukin-10 concentrations 
is part of anti-inflammatory response to immunotherapy.
In summary, longitudinal measurements of circulating interleukin-6, interleukin- 
10 and T-lymphocytes do not appear to offer information in addition to the MSKCC and 
GPS risk classifications in patients receiving immunotherapy for metastatic renal cancer.
I l l
Table 5.1 Baseline characteristics in patients undergoing alpha-interferon based
immunotherapy for metastatic renal cancer according completion of immunotherapy.
Immunotherapy Immunotherapy p-valu
not completed completed
(n= 12) ( n = l l )
Age group (<60/>60 yrs) 5 /7 4 /7 0.791
Sex (male/ female) 9 /3 9 /2 0.699
Prior surgical treatment
(curative/ cytoreductive/ none) 5 /2 /5 8/ 1/2 0.153
ECOG-PS (<1/>1) 12/0 11/0 1.000
Haemoglobin
(> 13/ < 13 g/dl M, > 11.5/ < 11.5 g/dl F) 4 /8 10/1 0.009
Adjusted Calcium (<2.5/ >2.5 ) 7 /5 9 /2 0.232
MSKCC (favourable/ intermediate/ poor) 2 /8 /2 7 /4 /0 0.016
Lactate dehydrogenase (<300/ >300 U/1) 11/1 11/0 1.000
Albumin (>35/ <35 g/1) 6 /6 10/1 0.037
C-reactive protein (<10/ >10 mg/1) 3 /9 6 / 5 0.156
GPS (0, 1, 2) 2 /5 /5 6 /4 / 1 0.033
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 8 /2 /2 9 /2 /0 0.239
Percentage total lymphocytes
(20-40/ 12.0-19.9/ 0-11.9 %) 4 /4 /4 7 /4 /0 0.046
CD4+ T-lymphocytes (%) 43 (30-62)* 41 (14-58)* 0.341
CD8+ T-lymphocytes (%) 27 (14-40)* 31 (12-50)* 0.844
Interleukin-6 (pg/ml) 39(12-133)* 15(12-41)* 0.074
Interleukin-10 (pg/ml) 28 (11-272)* 27 (12-238)* 0.424
Chemotherapy
(alpha-interferon/ alpha interferon plus) 11/1 8/3 0.242
* Median (range)
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Table 5.2 Baseline characteristics and cancer specific survival in patients undergoing
alpha-interferon based immunotherapy for metastatic renal cancer. Univariate analysis
Patients Hazard ratio p-valu
(n=23) (95%CI)
Age group (<60/>60 yrs) 9/ 14 1.35 (0.34-5.41) 0.673
Sex (male/ female) 18/5 1.01 (0.21-4.92) 0.989
Prior surgical treatment
(curative/ cytoreductive/ none) 13/ 3 /7 0.39 (0.12-1.21) 0.103
MSKCC (Favourable/ intermediate/ poor) 9 /1 2 /2 6.36(1.70-23.73) 0.006
Lactate dehydrogenase (<300/ >300 U/1) 22/1 0.57 (0.12-2.78) 0.150
GPS (0/ 1/ 2) 8/ 9 /6 4.27 (1.43-12.75) 0.010
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 1 7 /4 /2 1.60 (0.61-4.16) 0.340
Percentage total lymphocytes
(20-40/ 12.0-19.9/ 0-11.9%) 11 /8 /4 1.57 (0.66-3.72) 0.310
CD4+ T-lymphocytes (%) 42 (14-62)* 1.00 (0.94- 1.07) 0.950
CD84- T-lymphocytes (%) 29 (12-50)* 1.01 (0.94- 1.08) 0.772
Interleukin-6 (pg/ml) 17.7(11.8-132.9)* 1.02(1.00- 1.03) 0.055
Interleukin-10 (pg/ml) 27.2(11.0-272.4)* 1.01 (1 .00-1 .01) 0.038
Chemotherapy
(alpha-interferon/ alpha interferon plus) 19/4 0.58 (0.07-4.69) 0.614
Chemotherapy completed (no/ yes) 12/11 0.101
* Median (range)
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Table 5.3 Clinicopathological characteristics before and during chemotherapy in 
patients completing one cycle of treatment
Prior to During p-valu
Chemotherapy chemotherapy
(n=  11) (n = ll)
ECOG-PS (<1/>1) 11/0 10/1 0.317
Haemoglobin
(>13/ <13 g/dl M, >11.5/ <11.5 g/dl F 10/1 7 /4 0.083
Adjusted Calcium (<2.50/ >2.50 ) 9 /2 11/0 0.157
MSKCC (favourable/ intermediate/ poor) 7 /4 /0 6 /5 /0 0.564
Lactate dehydrogenase (<300/ >300 U/1) 11/0 11/0 1.000
Albumin (>35/ <35 g/1) 10/1 10/1 1.000
C-reactive protein (<10/ >10 mg/1) 6/5 4 /7 0.317
GPS (0, 1, 2) 6/4 /1 4 /6 /1 0.317
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 9 /2 /0 8/ 2/1 0.317
Percentage total lymphocytes
(20-40/ 12.0-19.9/ 0-11.9 %) 7 /4 /0 9 /2 / 0 0.414
CD4+ T-lymphocytes (%) 423 (29-58)* 47 (23-65)* 0.160
CD8+ T-lymphocytes (%) 27 (12-35)* 22 (14-32)* 0.725
Interleukin-6 (pg/ml) 16(13-41)* 19 (12-82)* 0.859
Interleukin-10 (pg/ml) 27 (12-238)* 81 (17-240)* 0.008
Chemotherapy
(alpha-interferon/ alpha interferon plus) 8/3
* Median (range)
114
6.0 Patient Study; The longitudinal relationship between circulating 
concentrations of C-reactive protein, interleukin-6 and interleukin-10 in 
patients undergoing resection for renal cancer
6.1 Introduction
In the third chapter, we reported the prognostic value of the systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C-reactive 
protein, in patients with primary operable renal cancer. This has been reported as a 
prognostic factor in patients undergoing potentially curative surgery for a number of solid 
tumours including colorectal (Nielsen et al, 2000; McMillan et al, 2003); gastro- 
oesophageal (Ikeda et al, 2003; Crumley et al, 2006), pancreatic (Jamieson et al, 2004) 
and urinary bladder (Hilmy et al, 2005) cancers.
However, the basis of the independent relationship between an elevated C- 
reactive protein concentration and poor survival in renal cancer is not clear. Specifically, 
it is not clear whether the systemic inflammatory response arises from the tumour per se 
or as a result of an impaired immune cytokine response. Interleukin-6 and interleukin-10 
are likely to be key cytokines in such a response since they appear to have stimulant and 
suppressive actions respectively on immune cells, in particular T-lymphocytes (Gabay & 
Kushner, 1999; Jee et al, 2001; Trika et al, 2003). Interleukin-6 is recognised as an 
autocrine growth factor for tumours, but also has a tumour suppressive role in promoting 
anti-tumour activity of macrophages (Trika et al, 2003). More recently, interleukin-10 
has been recognised to be an important immunosuppressive cytokine for the Thl anti­
tumour response and may be important in determining tumour growth and métastasés 
(Mocellin et al, 2005).
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The aim of the present study was to examine C-reactive protein, interleukin-6 and 
interleukin-10 concentrations before and following curative resection of renal cancer.
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6.2 Patients and Methods
Patients with benign and malignant renal disease, who underwent resection 
between March 2003 and October 2005 in the North Glasgow NHS Trust were included 
in the study. Patients were staged pathologically according to the 1997 UICC TNM 
classification of renal tumours (Sobin & Wittekind, 1997). Tumours were graded 
according to criteria set out by Fuhrman and coworkers (1982). Clinical stage and 
performance status (Eastern Cooperative Oncology Group, ECOG-ps) were recorded 
prior to surgery.
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
6.2.1 Experimental design
A blood sample was collected prior to resection for routine laboratory analysis of 
haemoglobin, white cell count, percentage lymphocyte count, albumin and C-reactive 
protein. The limit of detection of the assay was a C-reactive protein concentration lower 
than 6mg/l. The inter- and intra-assay variability of haemoglobin, white cell count, 
albumin and C-reactive, protein were less than 10%. A C-reactive protein concentration 
of greater than lOmg/1 was considered to indicate the presence of systemic inflammatory 
response (O'Gorman et al, 2000; McMillan et al, 2001). A further blood sample taken 
prior to surgery was centrifuged and the serum stored at -80°C prior to analysis of 
interleukin-6 and interleukin-10. Circulating concentrations of these cytokines were 
measured using an enzyme linked immunosorbent assay (ELISA) technique. The 
minimum detectable concentrations were two pg/ml for interleukin-6 and four pg/ml for
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interleukin-10 (Quantikine ELISA, R&D Systems Europe Ltd, Abingdon, UK). Inter- 
and intra-assay variability were less than 10% for both assays.
A second blood sample was obtained approximately three months following 
nephrectomy for routine laboratory analysis and cytokine quantification using the 
methods above.
6.2.2 Statistics
Data are presented as median and range. Comparisons between groups of patients 
were carried out using contingency table analysis (X^) as appropriate. Cytokine 
concentrations below the threshold of sensitivity of the respective assays were expressed 
as equal to this threshold. Where appropriate, data were tested for statistical significance 
using Mann-Whitney U test and the Wilcoxon signed rank test. As the distribution of C- 
reactive protein and the cytokines were skewed, they were logarithmically transformed 
prior to stepwise multiple regression analysis for the examination of independent 
associations with C-reactive protein. Univariate survival analysis was performed using 
the Kaplan-Meier method with the logrank test. Deaths up to the end of July 2006 were 
included in the analysis. Analysis was performed using SPSS software (SPSS Inc., 
Chicago, IL, USA).
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6.3 Results
The clinicopathological characteristics of patients who underwent resection for 
benign (n=12) and malignant (n=64) renal disease are shown in Table 6.1. Age, sex, 
ECOG-ps, haemoglobin, white cell count, percentage lymphocyte count, albumin and C- 
reactive protein were similar in the two groups. Circulating concentrations of both 
interleukin-6 and interleukin-10 (p<0.01) were higher and a greater proportion were 
elevated (p<0.05) in malignant compared with benign disease.
The renal cancer patients were grouped according to whether they had evidence of 
a systemic inflammatory response prior to nephrectomy (C-reactive protein >10 m g /1, 
Table 6.2). The groups were similar in terms of age, sex, tumour volume, Fuhrman grade, 
white cell count and percentage lymphocytes. In the inflammatory group T stage was 
higher (p<0.01), number of cytoreductive operations greater (p<0.05), both interleukin-6 
and interleukin-10 concentrations were higher (p<0.001) and elevated (p<0.10) compared 
with the non-inflammatory group. In contrast, haemoglobin (p<0.01) and albumin 
(p<0.10) concentrations and ECOG-ps (p<0.05) were lower in the inflammatory group. 
Tumour volume was weakly correlated with C-reactive protein (r^= 0.20, p=0.002), 
interleukin-6 (r^= 0.20, p=0.002) and interleukin-10 (r^= 0.24, p=0.001)
The minimum follow-up was seven months or until date of death; the median 
follow-up of the survivors was 25 months. During this period, 15 (20%) patients died: 11 
patients of their cancer and four of intercurrent disease. On univariate analysis, an 
elevated C-reactive protein concentration prior to resection was associated with reduction 
in cancer specific survival (p=0.014).
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In the cancer patients who had detectable circulating pre-operative C-reactive 
protein concentrations (n= 41), log transformed concentrations of C-reactive protein were 
significantly correlated with interleukin-6 (r^= 0.62, p<0.001. Figure la) and interleukin- 
10 (r^= 0.33, p<0.001. Figure lb). On multiple regression analysis of both interleukin-6 
and interleukin-10 on C-reactive protein, only interleukin-6 (r^= 0.63, p<0.001) retained 
independent significance. Interleukin-6 was significantly correlated with interleukin-10 
(r^= 0.49, p<0.001).
The clinicopathological characteristics of the patients who had undergone a 
potentially curative operation, prior to and approximately three months following 
nephrectomy, are shown in Table 6.3. The proportion of patients with a low percentage 
lymphocyte count, albumin and an elevated C-reactive protein concentration did not 
change significantly over this period. In contrast, there was a fall in performance status 
(p<0.01), haemoglobin (p<0.01) and an increase in white cell count during this period. 
Changes in interleukin-6 and interleukin-10 concentrations did not reach statistical 
significance.
In the cancer patients who had detectable circulating post-operative C-reactive 
protein concentrations (n= 35), log transformed concentrations of C-reactive protein were 
significantly correlated with those of interleukin-6 (r^= 0.66, p<0.001) and interleukin-10 
(r^= 0.33, p<0.001). On multiple regression analysis of both interleukin-6 and interleukin- 
10 on C-reactive protein, only interleukin-6 (r^= 0.66, p<0.001) retained independent 
significance. Interleukin-6 was significantly correlated with interleukin-10 (r^= 0.51,
p<0.001).
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6.4 Discussion
In the present study both interleukin-6 and interleukin-10 concentrations were 
greater in malignant compared with benign renal disease. Furthermore, both were directly 
associated with C-reactive protein and did not appear to normalise on resection of the 
primary renal tumour.
These results appear to contradict the report of Ljundberg and coworkers (1995) 
who, in a similar study design of 56 patients with stage I renal cancer reported that a 
number of acute phase proteins including C-reactive protein fell significantly 
approximately six months after resection. However, in the present study, when the 
analysis was confined to those patients with stage I disease, neither C-reactive protein, 
interleukin-6 or interleukin-10 appeared to normalise on resection of the primary tumour.
Galizia and coworkers (2002) in a similar study design in 50 patients with colon 
cancer reported that that both interleukin-6 and interleukin-10 concentrations fell by day 
16 following resection. However, it was of interest that, in their study, the median 
concentrations of interleukin-6 and interleukin-10, prior to surgery, were higher (8 and 15 
pg/ml respectively) compared with the results (3 and 5pg/ml respectively) in the present 
study. Nevertheless, consistent with the present study Galizia and coworkers (2002) 
observed that the majority of patients did not normalise their cytokine concentrations 
following radical resection.
The basis of the discrepancies between the present and previous studies is not 
clear. Nevertheless, the results of the present study are consistent with previous pre-/ 
post-operative C-reactive protein findings in colorectal, pancreatic and bladder cancer 
(McMillan et al, 2003; Jamieson et al, 2005; Hilmy et al, 2005). Furthermore, if there
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were to be a significant conversion rate from a systemic inflammatory state (C-reactive 
protein >10mg/l) to a non-inflammatory state (C-reactive protein <10mg/l) following 
resection then the prognostic value of markers of the systemic inflammatory response 
would be significantly degraded.
The elevated circulating concentrations of interleukin-6 and interleukin-10 
following resection of renal cancer may reflect a continuing Th-2 cytokine response since 
increased intra-tumoural CD4+ T-lymphocyte infiltrate has been shown to be associated 
with poor outcome, independent of grade, in patients with renal clear-cell cancer 
(Bromwich et al, 2003). This would be consistent with the observations in the present 
study that circulating interleukin-6 and interleukin-10 concentrations were not strongly 
correlated with tumour volume but were similarly correlated with each other before and 
after resection of the renal tumour. Moderation of this cytokine response may be 
important in the regulation of the systemic inflammatory response and warrants further 
clinical investigation.
Given the considerable variability of the effect of resection on C-reactive protein, 
interleukin-6 and interleukin-10 seen in the present study it would require a much larger 
study to absolutely preclude the possibility that surgical resection of renal cancer does not 
alter C-reactive protein, interleukin-6 and interleukin-10 concentrations. Nevertheless, the 
results of the present study would suggest that the presence of systemic inflammatory 
response is not solely determined by the elaboration of cytokines from the tumour.
In summary, an elevated pre-operative C-reactive protein was associated with 
increased tumour stage, interleukin-6 and interleukin-10 concentrations. However, 
resection of the primary tumour did not appear to be associated with significant
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normalisation of circulating concentrations of C-reactive protein, interleukin-6 or 
interleukin-10. Therefore, the presence of systemic inflammatory response is unlikely to 
be solely be determined by the tumour itself, but may be as a result of an impaired 
immune cytokine response in patients with renal cancer.
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Table 6.1 Clinicopathological characteristics in patients with benign and malignant
renal disease prior to nephrectomy
Benign disease Renal cancer p-valu
(n = 12) (n= 64)
Age group (<60/>60 yrs) 9 /3 35/ 29 0.194
Sex (male/ female) 4 /8 42/22 0.037
T stage (1 /2 / 3 /4) 2 7 /4 /2 1 /1 2
Tumour volume (cm^) 112(1-4864)
Fuhrman grade (1 /2 /3 /4 ) 8 /16 /21 /13
Operation (curative/ cytoreductive) 54/10
ECOG-PS (0/ 1) 12/0 53/11 0.123
Haemoglobin (>12/<12g/ dl) 9 /3 50/14 0.813
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 7/ 5 /0 48 /13 /3 0.486
Lymphocyte percentage
(20-40/ 12.0-19.9/0-11.9%) 10 /2 /0 43/15/ 6 0.199
Albumin (>35/ <35g/l) 11/0 59/3 0.459
C-reactive protein (<10/ >10mg/l) 8 /4 34/30 0.390
Interleukin-6 (pg/ml) <2 (<2-19) 4 (<2-142) 0.007
Interleukin-6 (<4/ >4pg/ml) 10/1 33/31 0.015
Interleukin-10 (pg/ml) <4 (<4-7) 6 (<4-66) 0.012
Interleukin-10 (<10/ >10pg/ml) 12/0 45/19 0.030
Median (range)
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Table 6.2 Clinicopathological characteristics of inflammatory and non-inflammatory
patients with renal cancer prior to nephrectomy.
C-reactive protein 
<10mg/l (n= 34)
C-reactive protein 
>10mg/l (n= 30)
p-value
Median <6mg/l Median 35mg/l
Age group (<60/>60 yrs) 17/17 18/12 0.426
Sex (male/ female) 23/11 19/11 0.719
T stage (1/ 2/ 3/ 4) 1 9 /2 /1 1 /2 8 /2 / 10/10 0.005
Tumour volume (cm^) 64(1-1331) 179 (9-4864) 0.123
Fuhrman grade (1 /2 /3 /4 ) 5 /1 1 /9 /6 3/ 5 /12 / 7 0.193
Operation (curative/ cytoreductive) 32/2 22/8 0.023
ECOG-PS (0/ 1) 32/2 21/9 0.011
Haemoglobin (>12/ <12g/ dl) 31/3 19/11 0.008
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 26/ 8/ 0 22/ 5/ 3 0.344
Lymphocyte percentage
(20-40/ 12.0-19.9/ 0-11.9 %) 26/ 6/ 2 17 /9 /4 0.100
Albumin (>35/ <35g/l) 33/0 26/3 0.060
Interleukin-6 (pg/ml) <2 (<2-20) 16 (<2-142) 0.001
Interleukin-6 (<4/ >4pg/ml) 22/ 12 11/ 19 0.026
Interleukin-10 (pg/ml) <4 (<4-66) 8 (<4-35) 0.013
Interleukin-10 (<10/ >10pg/ml) 27/7 18/12 0.092
Cancer specific survival (months)* 34.8 (32.6-37.1) 28.1 (23.1-33.0) 0.014
Median (range), *mean (95%CI)
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Table 6.3 Clinicopathological characteristics of patients with renal cancer prior to 
and approximately 3 months following potentially curative nephrectomy for localised 
renal cancer.
Pre-nephrectomy Post-nephrectomy p-value
(n = 54) (n= 54)
Age group (<60/>60 yrs) 26/28
Sex (male/ female) 34/20
T stage (1 /2 /3 /4 ) 2 7 /4 /2 1 /2
Tumour volume (cm^) 112(1-4864)
Fuhrman grade (1/ 2/ 3/ 4) 8/ 14/16/ 10
ECOG-PS (0/ 1) 48 /6 39/15 0.007
Haemoglobin (>12/ <12g/ dl) 45 /9 33/21 0.007
White cell count
(<8.5/8.5-11.0/>11.0 10 /^1) 4 1 /1 1 /2 31/ 20/3 0.029
Lymphocyte percentage
(20-40/ 12.0-19.9/ 0-11.9 %) 3 9 /11 /4 37 /12 /4 0.874
Albumin (>35/ <35g/l)" 51 /2 45/1 0.317
C-reactive protein (<10/ >10mg/l) 32/ 22 35/19 0.439
Interleukin-6 (pg/ml) ^ 3 (<2-99) <2 (<2-44) 0.227
10(18)" 6 (9 ^
Interleukin-6 (<4/ >4pg/ml) ^ 31/23 28/9 0.059
Interleukin-10 (pg/ml) ^ 5 (<4-66) 6 (<4-112) 0.056
12 (17)" 18 (26)"
Interleukin-10 (<10/ >10pg/ml)® 42/12 24/13 0.257
post-nephrectomy n= 37, mean (standard deviation), median (range)
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7.0 Conclusions
It has long been recognised that disease progression in cancer patients is not 
solely determined by the characteristics of the tumour, but also by aspects of the host 
response (Balwill & Mantovani, 2001). Indeed, there is increasing evidence that both the 
local and systemic inflammatory responses play an important role in the progression of a 
variety of common solid tumours (Coussens & Webb, 2002; Vakkila & Lotze, 2004). The 
use of immunotherapy in treating patients with metastatic renal cancer, and the rare 
phenomenon of spontaneous tumour regression, emphasise the immunogenic nature of 
renal cancer and the importance of host responses. The main aim of this thesis was to 
investigate the prognostic value of the systemic inflammatory response and its underlying 
mechanisms in patients with renal cancer. As the mechanisms underlying systemic 
inflammation may be different in patients with metastatic renal cancer compared to those 
with localised disease, these will be considered separately. Patients with metastatic renal 
cancer were studied in Chapters two and five, whilst Chapters three, four and six are 
based on studies of patients with primary operable renal cancer.
7.1 Metastatic renal cancer
In the second chapter it was shown that a cumulative inflammation-based 
Glasgow Prognostic Score had independent prognostic value in a study of 119 patients. 
Patients with GPS of 0, 1 and 2 had median survivals of 28, 11 and 3 months 
respectively. These results are consistent with the concept that the systemic inflammatory 
response is associated with profound catabolic effects on host protein metabolism 
(McMillan et al, 1998; Kotler, 2000) including albumin (Fearon et al., 1998). Indeed, in 
the thesis study, only 15% of the patients with hypoalbuminaemia had normal C-reactive
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protein concentrations. As such, the GPS quantifies the chronic systemic inflammatory 
response, which may lead to progressive nutritional and functional decline, subsequent 
cancer cachexia, and ultimately resulting in reduced survival.
A number of cytokine factors are thought to mediate increased concentrations of 
C-reactive protein in advanced cancer. In particular, interleukin-6 has been reported to 
account for 50-60% of the variation in circulating concentrations of C-reactive protein 
(Gabay & Kushner, 1999; McKeown et al, 2004). In Chapter five, it was shown that an 
elevated C-reactive protein concentration was associated with increases in both the “pro- 
inflammatory” cytokine interleukin-6 and the “immunosuppressive” cytokine interleukin- 
10 in 23 patients with metastatic renal cancer. In the same study following 
immunotherapy T-lymphocyte subsets, including the CD4 population, did not change 
despite a subsequent significant increase in interleukin-10 concentrations. These results 
would suggest that there may another source of interleukin-10. A recognised source of 
interleukin-10 secretion in vivo is the macrophage; and it may be that macrophage 
activation plays an important role in the activation systemic inflammatory response in 
patients with metastatic renal cancer. This hypothesis is consistent with the recent 
observation that increased tumour macrophage infiltration is associated with poor 
outcome, independent of subtype, in patients with renal cancer (Webster et al, 2006). 
Clearly, in the thesis study, macrophage activation may have occurred as a response to 
immunotherapy, with subsequent anti-inflammatory interleukin-10 secretion. It has yet to 
be determined if concentrations of interleukin-10 are independently associated with 
cancer specific survival in patients with metastatic renal cancer.
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Currently, the International Kidney Cancer Working Group is forming a 
collaborative effort to produce a unified prognostic scoring system for effective 
stratification of patients with metastatic renal cancer. It remains to be seen if this will 
include features of the systemic inflammatory response, but evidence from this thesis 
indicates the GPS may be a useful inclusion in the unified prognostic scoring system. 
Moreover, it is cheap, simple to assess and based on reliable analyses.
Whilst the mechanism of inflammation remains unclear, moderation of the 
systemic inflammatory response in patients with metastatic renal cancer could potentially 
reduce nutritional and functional decline and improve survival substantially. Based on 
our data, this survival benefit may as much as 17 months. Studies in patients with gastro­
intestinal cancer have reported that treatment with Non-Steroidal-Anti-Inflammatory 
Drugs may halt this functional decline (McMillan et al, 1999; Lundholm et al, 2004). 
However, a previous nephrectomy is a relative contra-indication to NSAID therapy as 
these can reduce renal blood flow, leading to renal impairment. As such, no studies have 
evaluated the role of NSAIDs in the management or palliation of patients with advanced 
renal cancer.
Alternatively, steroids could be used to suppress the systemic inflammatory 
response. Short courses of steroids are currently used in the management of the systemic 
inflammatory response in sepsis, guided by an abnormal short-synacthen test, a dynamic 
test of the hypothalamic-pituitary-adrenal axis. To date, few studies have examined the 
possibility of abnormal cortisol secretion in patients with advanced cancer or the role of 
steroids such as dexamethasone in metastatic renal cancer. However, they have been used 
empirically in certain circumstances such as cerebral métastasés. Future research could be
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tailored towards investigating the role of endogenous cortisol secretion in the moderation 
of the systemic inflammatory response in patients with metastatic renal cancer. The short- 
synacthen test could be used as a screening test prior to commencement of 
immunotherapy, or the new tyrosine kinase inhibitor drugs. Patients with abnormal 
cortisol secretion could then be treated with a short course of steroids and the systemic 
inflammatory response monitored.
7.2 Operable renal cancer
In Chapter three of this thesis the prognostic significance of C-reactive protein in 
111 patients undergoing potentially curative nephrectomy was reported. This significance 
was in addition to the Leibovich score. Both an elevated C-reactive protein and the 
Leibovich score were superior to the SSIGN score.
It was of interest that all but one patient had albumin concentrations within the 
normal range, and as such, the GPS could not be investigated for additional prognostic 
value in this cohort of patients. It may be that, unlike gastro-intestinal tumours where 
hypoalbuminaemia is a more common event, patients with renal cancer are relatively less 
nutritionally compromised at the time of their potentially curative surgery.
In Chapter six, the longitudinal relationship between the systemic inflammatory 
response, and circulating cytokines in patients with primary operable renal cancer was 
inverstigated. Interleukin-6 and interleukin-10 concentrations were both elevated in the 
presence of a systemic inflammatory response and were directly correlated. However, on 
multiple regression analysis only interleukin-6 was significantly correlated with C- 
reactive protein concentrations. Consequently, it may be that concentrations of
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interleukin-10 are increased in response to raised concentrations of interleukin-6 in a bid 
by the host to limit the systemic inflammatory response.
Following nephrectomy, the proportion of patients with an elevated C-reactive 
protein did not change significantly, nor did concentrations of interleukin-6 normalise. In 
contrast, there was a trend towards significance in the elevation of interleukin-10 
concentrations following nephrectomy. Therefore, the presence of systemic 
inflammatory response appears unlikely to be solely determined by the tumour itself, but 
may be a result of a disordered immune response. Again, the source of interleukin-10 
secretion in response to nephrectomy is unclear, but may be a macrophage-derived 
response, similar to the mechanism postulated during immunotherapy treatment. 
However, it remains to be seen if either interleukin-6 or interleukin-10 are superior to C- 
reactive protein in predicting cancer-specific survival these patients. Further follow-up of 
this cohort of patients will allow this important question to be addressed.
This longitudinal study, and the results from Chapter five suggest there may be a 
role for the macrophage in the development and persistence of the systemic inflammatory 
response. Whilst macrophages were not specifically examined during the studies, it 
would be of interest to repeat the analyses of circulating cytokines specifically associated 
with macrophages and the relationship with the systemic inflammatory response. In 
addition, macrophages have been implicated in angiogenesis via growth factors such as 
VEGF. If activation of macrophages leads to angiogenesis, and also secretion of 
Interleukin-10 which can suppress effective anti-tumour response, this potentially could 
be a mechanism for tumour progression and ultimately development of métastasés.
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There are a number of prognostic algorithms in use for patients with operable or 
localized renal cancer, but the majority of these are based on pathological factors. C- 
reactive protein concentrations are easily measured as part of a pre-operative work up, 
and add prognostic information to that provided by cross-sectional imaging prior to 
nephrectomy. Ultimately, the majority of patients fit for nephrectomy with localized 
disease will undergo resection. However, decision making regarding surgery in elderly 
patients, those with extensive co-morbidity, or high-risk locally advanced tumours may 
be influenced by the presence of a high inflammatory profile pre-operatively.
As with metastatic disease, moderation of the systemic inflammatory response 
could theoretically lead to improved time to progression, and cancer specific survival in 
patients with operable renal cancer. However, investigating this could require several 
years of essentially adjuvant therapy before effectiveness could be assessed. If steroids 
were used to suppress the systemic inflammatory response, complications relating to 
long-term use such as gastro-intestinal bleeding, osteopenia, and muscle wasting would 
be of concern. As such, it is likely any interventional study would need to investigate the 
effects of inflammation-modification in patients with metastatic renal cancer first, and an 
adjuvant study would only be possible if a significant survival benefit had been 
established for patients with metastatic disease.
7.3 Conclusions
In Chapter two the prognostic significance of the GPS in patients with metastatic 
renal cancer was reported. In Chapter three, an elevated C-reactive protein was shown to 
have prognostic value in addition to the Leibovich score in patients with primary operable 
renal cancer. In Chapter four, concentrations of circulating cytokines from both the Th-1
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and Th-2 lymphocytes were increased in the presence of a systemic inflammatory 
response. In Chapter five, a longitudinal study of patients commencing immunotherapy 
for metastatic renal cancer, immunotherapy did not alter circulating concentrations of T- 
lymphocytes though there was an increase in circulating interleukin-10. In the final study, 
a longitudinal study of patients undergoing potentially curative nephrectomy was 
performed. Elevated concentrations of C-reactive protein were associated with elevated 
interleukin-6 concentrations. At three months following nephrectomy, the proportion of 
patients with an evidence of a systemic inflammatory response had not altered 
significantly
In summary, the results of the present thesis are consistent with the hypothesis 
that the presence of a systemic inflammatory response is a significant factor in the 
functional decline and survival in patients with metastatic renal cancer, and the 
progression of disease in patients with primary operable renal cancer.
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